Dipeptidyl peptidase 1 inhibitors and uses thereof

Abstract

Provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A, R1, R2, R4, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor.

Description

Attorney Docket No.: INMD-209 / 01WO 315953-4493DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U. S. Provisional Patent Application No. 63 / 741,603, filed on January 3, 2025, the content of which is hereby incorporated by reference in its entirety for all purposes.BACKGROUND

[0002] Dipeptidyl peptidase 1 (DPP1; EC 3.4.14.1), also known as cathepsin C, is alysosomal cysteine protease belonging to the papain family having a molecular weight of 200 kDa. DPP1 was first discovered by Gutman and Fruton in 1948 (J Biol Chem, 174, 851-858); however, the cDNA of the human enzyme was first described in 1995 (Paris et al. 1995, FEBS Lett, 369, 326-330). DPP1 is the only member of the papain family that is functional as a tetramer, consisting of four identical subunits. Each subunit is composed of an N-terminal fragment, a heavy chain and a light chain (Dolenc et al. 1995, J Biol Chem, 270, 21626-21631).

[0003] DPP1 is constitutively expressed in many tissues with highest levels in lung, kidney, liver and spleen. DPP1 catalyzes the removal of dipeptides from the N-terminal end of polypeptide substrates with broad specificity. Recent data suggest that besides being an important enzyme in lysosomal protein degradation, DPP1 also functions as a key enzyme in the activation of granule serine proteases in cytotoxic T-lymphocytes and natural killer cells (granzymes A and B), mast cells (chymase and tryptase) and neutrophils (cathepsin G, neutrophil elastase and proteinase-3).

[0004] Mast cells are found in many tissues but are present in greater numbers along the epithelial linings of the body, such as the skin, respiratory tract and gastrointestinal tract. In humans, two types of mast cells have been identified. The T-type, which expresses only tryptase, and the MC-type, which expresses both tryptase and chymase. In humans, the T-type mast cells are located primarily in alveolar tissue and intestinal mucosa while the TC-type cells predominate in skin and conjunctiva. Tryptase and chymase appear to be important mediators of allergic diseases, being involved in processes of inflammation, bronchoconstriction and mucus secretion.

[0005] Neutrophils play a critical role in host defense against invading pathogens. Neutrophils are produced in the bone marrow and are fully mature when released into the circulation to take up their role as the first line of cellular defense. Pro-inflammatory mediators and chemotactic attractants activate neutrophils and draw them to the site of infection, where they act to engulfAttorney Docket No.: INMD-209 / 01WO 315953-4493bacteria by phagocytosis, assaulting them with an arsenal of anti-bacterial compounds that use both oxidative and non-oxidative methods of attack. The powerful serine protease, neutrophil elastase, is one of those anti-bacterial compounds that are clearly involved in destroying bacteria. Neutrophil elastase is released into the phagolysome surrounding the microorganism, which it proceeds to destroy. Neutrophil elastase is able to attack the outer membrane protein, OmpA, in gram-negative bacteria, helping to directly kill the pathogen by degrading its membrane, as well as enabling other anti-bacterial compounds to gain access to the pathogen. In addition, neutrophil elastase may help process other antibacterial compounds, converting them from inactive pro-peptides into their active states, such as for cathelicidin.

[0006] Yet neutrophil elastase can also cause problems for its host. It is one of the most destructive enzymes in the body, with the capability of degrading extracellular matrix proteins (including collagens, proteoglycan, fibronectin, platelet receptors, complement receptor, thrombomodulin, lung surfactant and cadherins) and key plasma proteins (including coagulation and complement factors, immunoglobulin, several proteases and protease inhibitors). Under physiological conditions, endogenous protease inhibitors, such as α1-antitrypsin, tightly regulate the activity of neutrophil elastase. However, at inflammatory sites, neutrophil elastase is able to evade regulation, and once unregulated it can induce the release of pro-inflammatory cytokines, such as interleukin-6 and interleukin-8, leading to acute lung injury. It can even impair host defense against infection by degrading phagocyte surface receptors and opsonins. Its negative role has been reported in a number of diseases characterized by tissue destruction and inflammation.

[0007] As such, there is a need in the art to provide novel DPP1 inhibitors in order to treat the aforementioned diseases, and others associated with DPP1 and neutrophil elastase.SUMMARY

[0008] The present disclosure provides a compound of Formula (I):Nor a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:Attorney Docket No.: INMD-209 / 01WO 315953-4493X1is -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-0-, -0-CH2-, -0-CH2- CH2-, -CH2-CH2-O- or -CH2-O-CH2-;X2is -CH2- or -CH2-CH2-; and X3is -NH-, -CH2-NH-, -NH-CH2-, -CH2-CH2-NH-, -NH-CH2-CH2- or - CH2-NH-CH2-; or, wherein Y1is -CH2-CH2-, -CH2-CH2CH2-, -CH2CH2NH-, -NHCH2CH2-, - CH2O-, -OCH2-, -CH2CH2O- or -OCH2CH2-;Y2is -CH2- or -CH2-CH2-;Y3is absent, -NH-, -CH2-, -CH2-NH- or -NH-CH2-; andY4is absent, -CH2- or -O-;Ring A is arylene, heteroarylene or heterocyclylene;R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R5is independently selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6alkyl, S(=O)2 alkyl, heterocyclyl heteroaryl, orILwherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(C 1-6 alkyl), N(Ci-ealkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH;wherein the compound is not one of the compounds disclosed in patent applications having publication numbers: CN114106005, W02016038007, WO2016016242 W02014140081, W02024094208, W02022053019, W02022053019, US20180125865, WO2016139355, WO2015032943, WO2015032942, W02014140078, W02014140075, WO2014140091, WO2013041497, and / or WO2012119941.

[0009] Each of the above listed publication is incorporated herein by reference in its entirety for all purposes.

[0010] The present disclosure also provides a compound of Formula (II):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein,Ring A is arylene, heteroarylene or heterocyclylene;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;ring B and ring C are each independently an aromatic ring optionally substituted with 1-3 group selected from R5or R6;X is CH2or NR6;W is N or CH;L is CH2, O, S(=O)2or NH;p is 0, 1, 2 or 3;U and V are each independently CH2, C(=O), O or NR6;q and r are each independently 0, 1, 2 or 3, provided that q and r are not both 0; ring E is cycloalkyl, aryl, heteroaryl or heterocyclyl;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6alkyl, S(=O)2alkyl, heterocyclyl, heteroaryl, orI wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R6is independently selected from H, Ci-6 alkyl, deuterated Ci-6 alkyl, Ci-6 alkylene-NH2, Ci-6 alkylene-NH(Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-NH(Ci- 6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), Ci-6 alkylene- heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(C 1-6 alkyl), N(Ci-ealkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6

[0011] The present disclosure also provides a compound of Formula (III):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:Ring A is arylene, heteroarylene or heterocyclylene;m is 0, 1, 2, 3 or 4;R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R4is independently selected from halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6,each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, C0N(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6alkyl, S(=O)2 alkyl, heterocyclyl heteroaryl, orILwherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

[0012] The present disclosure also provides compounds of Formula (1-1), (1-2), (la), (la-A), (la-B), (II-A), (II-B), (II-C), (II-D), (II-D ), (II-E), (III-l), (III-2), (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-F '), (III-G), (III-H), (III-I), (III-I ), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or pharmaceutically acceptable salts, stereoisomers, racemic forms, or deuterated forms thereof, as defined herein.

[0013] The present disclosure also provides compounds of Table A, Table B, or Table C, or pharmaceutically acceptable salts, stereoisomers, racemic forms, or deuterated forms thereof.

[0014] The present disclosure also provides a pharmaceutical composition comprising a compound disclosed herein (e.g., a compound of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-C), (II-D), (II-D ), (II-E), (III), (III-l), (III-2), (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-F ), (III-G), (III-H), (III-I), (III-I ), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or Table A, Table B, or Table C or a pharmaceuticallyAttorney Docket No.: INMD-209 / 01WO 315953-4493acceptable salt, a stereoisomer, a racemic form, or a deuterated form thereof), and a pharmaceutically acceptable adjuvant, diluent or carrier.

[0015] The present disclosure also provides a method for treating an obstructive disease of the airway in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (I), (I- 1), (1-2), (la), (la-A), (la- B), (II), (II-A), (II-B), (II-C), (II-D), (II-D ), (II-E), (III), (III-l), (III-2), (III-A), (III-B), (III- C), (III-D), (III-E), (III-F), (III-F '), (III-G), (III-H), (III-I), (III-I ), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or Table A, Table B, or Table C or a pharmaceutically acceptable salt, a stereoisomer, a racemic form, or a deuterated form thereof).

[0016] The present disclosure also provides a method for treating chronic rhinosinusitis in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-C), (II-D), (II-D ), (II-E), (III), (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-F ), (III-G), (III-H), (III-I), (III-I ), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or Table A, Table B, or Table C or a pharmaceutically acceptable salt, a stereoisomer, a racemic form, or a deuterated form thereof).

[0017] The present disclosure also provides a method for treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-C), (II-D), (II-D ), (II-E), (III), (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-F ), (III-G), (III-H), (III-I), (III-I ), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or Table A, Table B, or Table C or a pharmaceutically acceptable salt, a stereoisomer, a racemic form, or a deuterated form thereof).

[0018] The present disclosure also provides a method for treating lupus nephritis in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-C), (II-D), (II-D ), (II-E), (III), (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-F ), (III-G), (III-H), (III-I), (III-F), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic- D) or (Ic-E), or Table A, Table B, or Table C or a pharmaceutically acceptable salt, a stereoisomer, a racemic form, or a deuterated form thereof).

[0019] The present disclosure also provides a method for treating rheumatoid arthritis in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-C), (II-D), (II-D ), (II-E), (III), (III-A), (III-B), (III-C), (III-D), (III-E),Attorney Docket No.: INMD-209 / 01WO 315953-4493(III-F), (III-F´), (III-G), (III-H), (III-I), (III-I´), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or Table A, Table B, or Table C or a pharmaceutically acceptable salt, a stereoisomer, a racemic form, or a deuterated form thereof).

[0020] The present disclosure also provides a method for treating inflammatory bowel disease in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-C), (II-D), (II-D´), (II-E), (III), (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-F´), (III-G), (III-H), (III-I), (III-I´), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or Table A, Table B, or Table C or a pharmaceutically acceptable salt, a stereoisomer, a racemic form, or a deuterated form thereof).

[0021] The present disclosure also provides a method for treating pulmonary fibrosis in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-C), (II-D), (II-D´), (II-E), (III), (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-F´), (III-G), (III-H), (III-I), (III-I´), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or Table A, Table B, or Table C or a pharmaceutically acceptable salt, a stereoisomer, a racemic form, or a deuterated form thereof).

[0022] The present disclosure also provides a method for treating COPD in a patient in need thereof, comprising administering to the patient an effective amount of a compound disclosed herein (e.g., a compound of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-C), (II-D), (II-D´), (II-E), (III), (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-F´), (III-G), (III-H), (III-I), (III-I´), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or Table A, Table B, or Table C or a pharmaceutically acceptable salt, a stereoisomer, a racemic form, or a deuterated form thereof).DETAILED DESCRIPTION

[0023] Throughout this disclosure, various patents, patent applications and publications are referenced. The disclosures of these patents, patent applications and publications in their entireties are incorporated into this disclosure by reference for all purposes in order to more fully describe the state of the art as known to those skilled therein as of the date of this disclosure. This disclosure will govern in the instance that there is any inconsistency between the patents, patent applications and publications cited and this disclosure.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0024] Definitions

[0025] Listed below are definitions of various terms used in the specification and claims to describe the present disclosure.

[0026] Unless defined otherwise, all technical and scientific terms used in this disclosure have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0027] The term “about” when immediately preceding a numerical value means a range encompassing said numerical value plus or minus an acceptable amount of variation in the art (e.g., plus or minus 10% of that value). For example, “about 50” can mean 45 to 55, “about 25,000” can mean 22,500 to 27,500, etc., unless the context of the disclosure indicates otherwise, or is inconsistent with such an interpretation. For example in a list of numerical values such as “about 49, about 50, about 55,...”, “about 50” means a range extending to less than half the interval(s) between the preceding and subsequent values, e.g., more than 49.5 to less than 50.5. Furthermore, the phrases “less than about” a value or “greater than about” a value should be understood in view of the definition of the term “about” provided herein. Similarly, the term “about” when preceding a series of numerical values or a range of values (e.g., “about 10, 20, 30” or “about 10-30”) refers, respectively to all values in the series, or the endpoints of the range.

[0028] The terms below, as used herein, have the following meanings, unless indicated otherwise:

[0029] “Cyano” refers to the -CN radical.

[0030] “Hydroxy” or “hydroxyl” refers to the -OH radical.

[0031] “ Oxo” refers to the =0 substituent.

[0032] “Alkyl” or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain radical having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 12 are included. An alkyl comprising up to 12 carbon atoms is a C1-C12 alkyl, an alkyl comprising up to 10 carbon atoms is a C1-C10 alkyl, an alkyl comprising up to 6 carbon atoms is a Ci-Ce alkyl and an alkyl comprising up to 5 carbon atoms is a C1-C5 alkyl. A C1-C5 alkyl includes C5 alkyls, C4 alkyls, C3 alkyls, C2 alkyls and Ci alkyl (i.e., methyl). A Ci-Ce alkyl includes all moieties described above for C1-C5 alkyls but also includes Ce alkyls. A C1-C10 alkyl includes all moieties described above for C1-C5 alkyls and Ci-Ce alkyls, but also includes C7, Cs, C9 and C10 alkyls. Similarly, a C1-C12 alkyl includes all the foregoing moieties, but also includes C11 and C12 alkyls. Non-limiting examples of C1-C12 alkyl include methyl, ethyl, n-propyl, i-propyl,Attorney Docket No.: INMD-209 / 01WO 315953-4493sec-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.

[0033] “Alkylene” or “alkylene chain” refers to a fully saturated, straight or branched divalent hydrocarbon chain radical, and having from one to twelve carbon atoms. Non-limiting examples of C1-C12 alkylene include methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain can be optionally substituted.

[0034] “Alkenyl” or “alkenyl group” refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds. Each alkenyl group is attached to the rest of the molecule by a single bond. Alkenyl group comprising any number of carbon atoms from 2 to 12 are included. An alkenyl group comprising up to 12 carbon atoms is a C2-C12 alkenyl, an alkenyl comprising up to 10 carbon atoms is a C2-C10 alkenyl, an alkenyl group comprising up to 6 carbon atoms is a C2-C6 alkenyl and an alkenyl comprising up to 5 carbon atoms is a C2-C5 alkenyl. A C2-C5 alkenyl includes C5 alkenyls, C4 alkenyls, C3 alkenyls, and C2 alkenyls. A C2-C6 alkenyl includes all moieties described above for C2-C5 alkenyls but also includes Ce alkenyls. A C2-C10 alkenyl includes all moieties described above for C2-C5 alkenyls and C2-C6 alkenyls, but also includes C7, Cs, C9 and C10 alkenyls. Similarly, a C2-C12 alkenyl includes all the foregoing moieties, but also includes C11 and C12 alkenyls. Non-limiting examples of C2-C12 alkenyl include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-l -propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1 -pentenyl, 2-pentenyl, 3 -pentenyl, 4-pentenyl, 1 -hexenyl, 2-hexenyl, 3 -hexenyl, 4-hexenyl, 5-hexenyl, 1 -heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1 -undecenyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, and 11-dodecenyl. Unless stated otherwise specifically in the specification, an alkenyl group can be optionally substituted.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0035] “Alkenylene” or “alkenylene chain” refers to a straight or branched divalent hydrocarbon chain radical, having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds. Non-limiting examples of C2-C12 alkenylene include ethene, propene, butene, and the like. The alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain can be optionally substituted.

[0036] “Alkynyl” or “alkynyl group” refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds. Each alkynyl group is attached to the rest of the molecule by a single bond. Alkynyl group comprising any number of carbon atoms from 2 to 12 are included. An alkynyl group comprising up to 12 carbon atoms is a C2-C12 alkynyl, an alkynyl comprising up to 10 carbon atoms is a C2-C10 alkynyl, an alkynyl group comprising up to 6 carbon atoms is a C2-C6 alkynyl and an alkynyl comprising up to 5 carbon atoms is a C2-C5 alkynyl. A C2-C5 alkynyl includes C5 alkynyls, C4 alkynyls, C3 alkynyls, and C2 alkynyls. A C2-C6 alkynyl includes all moieties described above for C2-C5 alkynyls but also includes Ce alkynyls. A C2-C10 alkynyl includes all moieties described above for C2-C5 alkynyls and C2-C6 alkynyls, but also includes C7, Cs, C9 and C10 alkynyls. Similarly, a C2-C12 alkynyl includes all the foregoing moieties, but also includes C11 and C12 alkynyls. Non-limiting examples of C2-C12 alkenyl include ethynyl, propynyl, butynyl, pentynyl and the like. Unless stated otherwise specifically in the specification, an alkynyl group can be optionally substituted.

[0037] “Alkynylene” or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain radical, having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds. Non-limiting examples of C2-C12 alkynylene include ethynylene, propargylene and the like. The alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkynylene chain can be optionally substituted.

[0038] “Alkoxy” refers to a radical of the formula -ORa where Ra is an alkyl, alkenyl or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group can be optionally substituted.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0039] “Alkylamino” refers to a radical of the formula -NHRa or -NRaRa where each Ra is, independently, an alkyl, alkenyl or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group can be optionally substituted.

[0040] “Aryl” refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon ring atoms and at least one aromatic ring. For purposes of this disclosure, the aryl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused, bridged, or spiro ring systems. Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. In embodiments where “L” is aryl, the aryl radical is a diradical. Unless stated otherwise specifically in the specification, the term “aryl” is meant to include aryl radicals that are optionally substituted.

[0041] “Aralkyl” or “arylalkyl” refers to a radical of the formula -Rb-Rc where Rb is an alkylene group as defined above and Rcis one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an aralkyl group can be optionally substituted.

[0042] “Carbocyclyl,” “carbocyclic ring” or “carbocycle” refers to a rings structure, wherein the atoms which form the ring are each carbon. Carbocyclic rings can comprise from 3 to 20 carbon atoms in the ring. Carbocyclic rings include cycloalkyl, cycloalkenyl and cycloalkynyl as defined herein. Unless stated otherwise specifically in the specification, a carbocyclyl group can be optionally substituted.

[0043] “Cycloalkyl” refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon radical consisting solely of carbon and hydrogen atoms, which can include fused, bridged, or spiro ring systems, having from three to twenty carbon atoms, e.g., having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group can be optionally substituted.

[0044] “Cycloalkenyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon double bonds, which can include fused, bridged, or spiro ring systems, having from three toAttorney Docket No.: INMD-209 / 01WO 315953-4493twenty carbon atoms, e.g., having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkenyl radicals include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, cycloctenyl, and the like. Polycyclic cycloalkenyl radicals include, for example, bicyclo[2.2.1]hept-2-enyl and the like. Unless otherwise stated specifically in the specification, a cycloalkenyl group can be optionally substituted.

[0045] “Cycloalkynyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon triple bonds, which can include fused, bridged, or spiro ring systems, having from three to twenty carbon atoms, e.g., having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkynyl radicals include, for example, cycloheptynyl, cyclooctynyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkynyl group can be optionally substituted.

[0046] “Cycloalkylalkyl” refers to a radical of the formula -Rb-Rd where Rb is an alkylene, alkenylene, or alkynylene group as defined above and Rd is a cycloalkyl, cycloalkenyl, cycloalkynyl radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group can be optionally substituted.

[0047] “Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group can be optionally substituted.

[0048] “Haloalkenyl” refers to an alkenyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1 -fluoropropenyl, 1,1-difluorobutenyl, and the like. Unless stated otherwise specifically in the specification, a haloalkenyl group can be optionally substituted.

[0049] “Haloalkynyl” refers to an alkynyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1 -fluor opropynyl, 1 -fluor obutynyl, and the like. Unless stated otherwise specifically in the specification, a haloalkynyl group can be optionally substituted.

[0050] “Heterocyclyl” “heterocyclic ring” or “heterocycle” refers to a stable 3- to 20-membered non-aromatic, saturated or partially unsaturated ring radical which consists of two to nineteen carbon ring atoms and from one to six heteroatoms as ring atoms selected from nitrogen, oxygen or sulfur, at least one non-aromatic, saturated or partially unsaturated ring containing at least one heteroatom as a ring atom. Unless stated otherwise specifically in theAttorney Docket No.: INMD-209 / 01WO 315953-4493specification, the heterocyclyl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused, bridged, or spiro ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical can be optionally oxidized; the nitrogen atom can be optionally quatemized; and the heterocyclyl radical can be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. In embodiments where “L” is heterocyclyl, the heterocyclyl radical is a diradical. Unless stated otherwise specifically in the specification, a heterocyclyl group can be optionally substituted.

[0051] “Heterocyclylalkyl” refers to a radical of the formula -Rb-Re where Rb is an alkylene group as defined above and Re is a heterocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a heterocycloalkyl group can be optionally substituted.

[0052] “N-heterocyclyl” refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. Unless stated otherwise specifically in the specification, a N-heterocyclyl group can be optionally substituted.

[0053] “Heteroaryl” refers to a 5- to 20-membered ring system radical comprising two to nineteen carbon ring atoms, one to six heteroatoms as ring atoms selected from nitrogen, oxygen and sulfur, and at least one aromatic ring. For purposes of this disclosure, when the heteroaryl ring is a polycyclic ring (e.g., bicyclic, tricyclic, or tetracyclic ring), the at least one aromatic does not need to contain a heteroatom (e.g., indoline, 2,3-dihydrobenzo[d]oxazole, benzo[d]oxazol-2(3H)-one, etc.). For purposes of this disclosure, the heteroaryl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused, bridged, or spiro ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical can be optionally oxidized; the nitrogen atom can be optionally quatemized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl,Attorney Docket No.: INMD-209 / 01WO 315953-4493benzothienyl (benzothiophene), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophene, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1 -phenyl- IH-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophene (i.e. thienyl). In embodiments where “L” is heteroaryl, the heteroaryl radical is a diradical. Unless stated otherwise specifically in the specification, a heteroaryl group can be optionally substituted.

[0054] “N-heteroaryl” refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an N-heteroaryl group can be optionally substituted.

[0055] “Heteroarylalkyl” refers to a radical of the formula -Rb-Rf where Rb is an alkylene chain as defined above and Rf is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group can be optionally substituted.

[0056] “Thioalkyl” refers to a radical of the formula -SRa where Ra is an alkyl, alkenyl, or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group can be optionally substituted.

[0057] The term “substituted” used herein means any of the above groups (i.e., alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, carbocyclyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and / or heteroarylalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0058] “ Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced with -NRgRh, -NRgC(=O)Rh, -NRgC(=O)NRgRh, -NRgC(=O)ORh, -NRgSO2Rh, -OC(=O)NRgRh, -ORg, -SRg, -SORg, -SO2Rg, -OSO2Rg, -SO2ORg, =NSO2Rg, and -SChNRgRh. “Substituted also means any of the above groups in which one or more hydrogen atoms are replaced with -C(=O)Rg, -C(=O)ORg, -C(=O)NRgRh, -CH2SO2Rg, -CH2SO2NRgRh. In the foregoing, Rgand Rh are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and / or heteroarylalkyl. “Substituted” further includes any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and / or heteroarylalkyl group. In addition, each of the foregoing substituents can also be optionally substituted with one or more of the above substituents._

[0059] As used herein, the symbol “ I ” or “ ‘ ” (hereinafter can be referred to as “a point of attachment bond”) denotes a bond that is a point of attachment between two chemical entities, one of which is depicted as being attached to the point of attachment bond and the other of which is not depicted as being attached to the point of attachment bond. For example,XY-i— XY— |“! ” or “ 1 ” indicates that the chemical entity “XY” is bonded to another chemical entity via the point of attachment bond. Furthermore, the specific point of attachment to the non-depicted chemical entity can be specified by inference.

[0060] In this specification, unless stated otherwise, the term “pharmaceutically acceptable” is used to characterize a moiety (e.g., a salt, dosage form, or excipient) as being appropriate for use in accordance with sound medical judgment. In general, a pharmaceutically acceptable moiety has one or more benefits that outweigh any deleterious effect that the moiety may have. Deleterious effects may include, for example, excessive toxicity, irritation, allergic response, and other problems and complications.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0061] The term “pharmaceutically acceptable salt” includes both acid and base addition salts. Pharmaceutically acceptable salts include those obtained by reacting the active compound functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc. Those skilled in the art will further recognize that acid addition salts may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.

[0062] The compounds of the disclosure, or their pharmaceutically acceptable salts can contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as (R)- or (5)- or, as (D)- or (L)- for amino acids. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms whether or not they are specifically depicted herein. Optically active (+) and (-), (R)- and (5)-, or (D)- and (L)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.

[0063] A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposable mirror images of one another. Stereoisomer includes racemates.

[0064] The term “treating” as used herein with regard to a patient, refers to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and / or a prophylactic benefit. Therapeutic benefit refers to any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment. The term “treating” in one embodiment, includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in the patient that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or displayAttorney Docket No.: INMD-209 / 01WO 315953-4493clinical or subclinical symptoms of the state, disorder or condition; (2) inhibiting the state, disorder or condition (e.g., arresting, reducing or delaying the development of the disease, or a relapse thereof in case of maintenance treatment, of at least one clinical or subclinical symptom thereof); (3) relieving the condition (for example, by causing regression, or reducing the severity of the state, disorder or condition or at least one of its clinical or subclinical symptoms).

[0065] An “effective amount” means the amount of a compound or pharmaceutical formulation, that when administered to a patient for treating a state, disorder or condition is sufficient to affect such treatment.

[0066] The term “therapeutically effective” applied to dose or amount refers to that quantity of a compound or pharmaceutical formulation that is sufficient to result in a desired clinical benefit after administration to a patient in need thereof. A “therapeutically effective amount”, in some embodiments, is a dose or amount of a compound or pharmaceutical formulation that is sufficient to result in prophylaxis after administration to a patient in need thereof.

[0067] The terms “subject,” “individual,” and “patient” are used interchangeably herein to refer to a vertebrate, such as a mammal. The mammal may be, for example, a mouse, a rat, a rabbit, a cat, a dog, a pig, a sheep, a horse, a non-human primate (e.g., cynomolgus monkey, chimpanzee), or a human.

[0068] Compounds

[0069] In embodiments of the present disclosure, DPP1 inhibitors are provided, and the DPP1 inhibitor is a compound of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-C), (II-D), (II-D ), (II-E), (III), (III-l), (III-2), (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-F ), (III-G), (III-H), (III-I), (III-F), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or Table A, Table B, or Table C, or a pharmaceutically acceptable salt, a stereoisomer, a racemic form, or a deuterated form thereof, wherein the compound is not a compound disclosed in one or more of the following patent application publications: CN114106005, W02016038007, WO2016016242 W02014140081, W02024094208, W02022053019, W02022053019, US20180125865, WO2016139355, WO2015032943, WO2015032942, W02014140078, W02014140075, W02014140091, WO2013041497, and / or WO2012119941, the entirety of each of which is incorporated herein by reference.

[0070] In one embodiment, the present disclosure provides a compound of Formula (I):R’ ' No L^^ / (R4)mIA1CD,Attorney Docket No.: INMD-209 / 01WO 315953-4493or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:R1isX1a A) whereinX1is -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O-, -O-CH2-, -O-CH2- CH2-, -CH2-CH2-O- or -CH2-O-CH2-;X2is -CH2- or -CH2-CH2-; andX3is -NH-, -CH2-NH-, -NH-CH2-, -CH2-CH2-NH-, -NH-CH2-CH2- or - CH2-NH-CH2-; or(R3)n~r__Y2 y4^Y3^ / ', whereinY1is -CH2-CH2-, -CH2-CH2CH2-, -CH2CH2NH-, -NHCH2CH2-, - CH2O-, -OCH2-, -CH2CH2O- or -OCH2CH2-;Y2is -CH2- or -CH2-CH2-;Y3is absent, -NH-, -CH2-, -CH2-NH- or -NH-CH2-; andY4is absent, -CH2- or -O-;Ring A is arylene, heteroarylene or heterocyclylene;R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R4is independently selected from halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, i— L— ( )S(=O)2alkyl, heterocyclyl, heteroaryl, or » O, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(C 1-6 alkyl), N(Ci-ealkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH;wherein the compound is not a compound disclosed in one or more of the following patent application publications: CN114106005, W02016038007, WO2016016242 W02014140081, W02024094208, W02022053019, W02022053019, US20180125865, WO2016139355, WO2015032943, WO2015032942, W02014140078, W02014140075, W02014140091, WO2013041497, or WO2012119941, the entirety of each of which is incorporated herein by reference.

[0071] In one embodiment, the present disclosure provides a compound of Formula (1-1):N(Ror a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:R1isAttorney Docket No.: INMD-209 / 01WO 315953-4493X1(R3)n“fe / a.) x3^y ' whereinX1is -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O-, -O-CH2-, -O-CH2- CH2-, -CH2-CH2-O- or -CH2-O-CH2-;X2is -CH2- or -CH2-CH2-; andX3is -NH-, -CH2-NH-, -NH-CH2-, -CH2-CH2-NH-, -NH-CH2-CH2- or - CH2-NH-CH2-; or(R3)n~r__Y2 y4\Y3A / b) ', whereinY1is -CH2-CH2-, -CH2-CH2CH2-, -CH2CH2NH-, -NHCH2CH2-, - CH2O-, -OCH2-, -CH2CH2O- or -OCH2CH2-;Y2is -CH2- or -CH2-CH2-;Y3is absent, -NH-, -CH2-, -CH2-NH- or -NH-CH2-; andY4is absent, -CH2- or -O-;R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH,Attorney Docket No.: INMD-209 / 01WO 315953-4493COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl,|_ i_— (T)S(=0)2alkyl, heterocyclyl heteroaryl, or’ ' — ', wherein L is Ci-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OCi-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(CI-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(C 1-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH;wherein the compound is not a compound disclosed in one or more of the following patent application publications: CN114106005, WO2016038007, WO2016016242 WO2014140081, W02024094208, W02022053019, W02022053019, US20180125865, WO2016139355, WO2015032943, WO2015032942, W02014140078, W02014140075, W02014140091, WO2013041497, or WO2012119941, the entirety of each of which is incorporated herein by reference.

[0072] In one embodiment, the present disclosure provides a compound of Formula (1-2):R1(1-2),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:R1iswhereinX1is -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O-, -O-CH2-, -O-CH2- CH2-, -CH2-CH2-O- or -CH2-O-CH2-;X2is -CH2- or -CH2-CH2-; andAttorney Docket No.: INMD-209 / 01WO 315953-4493X3is -NH-, -CH2-NH-, -NH-CH2-, -CH2-CH2-NH-, -NH-CH2-CH2- or - CH2-NH-CH2-; or(R3)n-r__Y2 y4b) ', whereinY1is -CH2-CH2-, -CH2-CH2CH2-, -CH2CH2NH-, -NHCH2CH2-, - CH2O-, -OCH2-, -CH2CH2O- or -OCH2CH2-;Y2is -CH2- or -CH2-CH2-;Y3is absent, -NH-, -CH2-, -CH2-NH- or -NH-CH2-; andY4is absent, -CH2- or -O-;Ring A is polycyclic arylene, polycyclic heteroarylene or polycyclic heterocyclylene; R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, i— L— ( )S(=O)2alkyl, heterocyclyl, heteroaryl, or » O, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionallyAttorney Docket No.: INMD-209 / 01WO 315953-4493substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(C 1-6 alkyl), N(Ci-ealkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH;wherein the compound is not a compound disclosed in one or more of the following patent application publications: CN114106005, W02016038007, WO2016016242 W02014140081, W02024094208, W02022053019, W02022053019, US20180125865, WO2016139355, WO2015032943, WO2015032942, W02014140078, W02014140075, W02014140091, WO2013041497, or WO2012119941, the entirety of each of which is incorporated herein by reference.

[0074] In one embodiment, the present disclosure provides a compound of Formula (la),Attorney Docket No.: INMD-209 / 01WO 315953-4493or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinX1is -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O-, -O-CH2-, -O-CH2-CH2-, -CH2-CH2-O- or -CH2-O-CH2-;X2is -CH2- or -CH2-CH2-;X3is -NH-, -CH2-NH-, -NH-CH2-, -CH2-CH2-NH-, -NH-CH2-CH2- or -CH2-NH-CH2-; Ring A is arylene, heteroarylene or heterocyclylene;R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, i— L—S(=O)2alkyl, heterocyclyl, heteroaryl, or ⊢L—(E), wherein L is CH2, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-Attorney Docket No.: INMD-209 / 01WO 315953-44936 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), Ci-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(C 1-6 alkyl), N(Ci-ealkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH;wherein the compound is not a compound disclosed in one or more of the following patent application publications: W02014140081, W02016038007, WO 2016016242 or CN 114106005, the entirety of each of which is incorporated herein by reference.

[0075] In one embodiment, the present disclosure provides a compound of Formula (la- A)(la-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein X1, X2, X3, R2, R3, R4, n and m are as defined in formula (la);wherein the compound is not a compound disclosed in one or more of the following patent application publications: W02014140081, W02016038007, WO 2016016242 or CN 114106005, the entirety of each of which is incorporated herein by reference.

[0076] In one embodiment, the present disclosure provides a compound of Formula (la-B):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein,X1is -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O-, -O-CH2-, -O-CH2-CH2-, -CH2- CH2-O- or -CH2-O-CH2-;X2is -CH2- or -CH2-CH2-;X3is -NH-, -CH2-NH-, -NH-CH2-, -CH2-CH2-NH-, -NH-CH2-CH2- or -CH2-NH-CH2-; Ring A is polycyclic arylene, polycyclic heteroarylene or polycyclic heterocyclylene; R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S orAttorney Docket No.: INMD-209 / 01WO 315953-4493O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl,I— L—S(=O)2alkyl, heterocyclyl, heteroaryl, or⊢L—(E), wherein L is CH2, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

[0077] In the compounds of Formula (I), (la) or (la-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, it is provided thatAttorney Docket No.: INMD-209 / 01WO 315953-4493CN'b -Sk(R3)n43}( / pc when R1or isM, then R2is not ^NH O 0J / J ^, ^**1, ANvJwww*,,,,,0 Oo o <?MMwJvww* wvlsw y 01* § •M'"***0X1when R1or is, then R2is not „X~or• o o— fT'XlP> O X3^ when R1or is, then R2is not 0rr^x1(R^n-P^k X3^x— N1when R1or isH, then R2is not or CNS'Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0078] In the compounds of Formula (I), (la) or (la-A), or a pharmaceutically acceptable salt,Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0079] In the compounds of Formula (I), (la) or (la-A), or a pharmaceutically acceptable salt,X1< R3)""“X3 a stereoisomer, or a deuterated form thereof, when R1or, then R2

[0080] In the compounds of Formula (I), (la) or (la-A), or a pharmaceutically acceptable salt,_x1< R^n~^y HIC a stereoisomer, or a deuterated form thereof, when R1or' is thenR2is not

[0081] In the compounds of Formula (I), (la) or (la-A), or a pharmaceutically acceptable salt,a stereoisomer, or a deuterated form thereof, when R1orthen R2

[0082] In the compounds of Formula (I), (la) or (la- A), or a pharmaceutically acceptable salt,a stereoisomer, or a deuterated form thereof, when R1orthen R2Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0083] In the compounds of Formula (I), (la) or (la-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, when R1orthen

[0084] In the compounds of Formula (I), (la) or (la-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, when R1orthen R2

[0085] In the compounds of Formula (I), (la) or (la-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, the compound is not

[0086] In one embodiment, the present disclosure provides a compound of Formula (II):(II),Attorney Docket No.: INMD-209 / 01WO 315953-4493or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein,Ring A is arylene, heteroarylene or heterocyclylene;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;ring B and ring C are each independently an aromatic ring optionally substituted with 1-3 group selected from R5or R6;X is CH2or NR6;W is N or CH;L is CH2, O, S(=O)2or NH;p is 0, 1, 2 or 3;U and V are each independently CH2, C(=O), O or NR6;q and r are each independently 0, 1, 2 or 3, provided that q and r are not both 0; ring E is cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R5is independently selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl, heterocyclyl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;each R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(C 1-6 alkyl), N(Ci-ealkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl;provided that the compound of Formula (II) is not

[0087] In embodiments of the compound of Formula (II), or a pharmaceutically acceptable (R4)mN=N ~R6; m is 0 or 1; n is 0; R2is; R4is halogen; and R6is H or C1-3 alkyl. In embodiments, m is 0. In embodiments, m is 1 and R4is F. In embodiments, R6is CH3.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0088] In one embodiment, the present disclosure provides a compound of Formula (II-A):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein,Ring A is arylene, heteroarylene or heterocyclylene;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;ring B and ring C are each independently an aromatic ring optionally substituted with 1-3 group selected from R5or R6;Attorney Docket No.: INMD-209 / 01WO 315953-4493X is CH2or NR6;W is N or CH;L is CH2, O, S(=O)2orNH;ring E is cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;p is 0, 1, 2 or 3;U and V are each independently CH2, C(=O), O or NR6;q and r are each independently 0, 1, 2 or 3, provided that q and r are not both 0; each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl, heterocyclyl or heteroaryl, wherein the OH, NH2, alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;each R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(CI-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(C 1-6 alkyl), N(Ci-6alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl.

[0089] In embodiments of the compound of Formula (II- A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2; and R3is F, Cl, CH3, or CH3OH.In a further embodiment, nis 0, andAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0090] In embodiments of Formula (II-A), or a pharmaceutically acceptable salt, a O'R6(R5)P^ I stereoisomer, or a deuterated form thereof, R2is; p is 0, 1, 2 or 3; each R5is independently halogen, oxo, Ci-6 alkyl, OCi-6 alkyl or CN; R6is H, Ci-6 alkyl, Ci-6 alkylene-N(C1-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a further embodiment, p is 0, 1, 2 or 3; each R5is independently halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl, C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In yet a further embodiment, p is 0; and R6is C1-6 alkyl. In yet even a further embodiment, R6is CH3.

[0091] In embodiments of the compound of Formula (II-A), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof,orand m is 0 or 1. In some embodiments, orrepresents the point of attachment to R2. In embodiments,embodiments,, wherein the asterisk (*) represents the point of attachment to R2.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0092] In embodiments of the compound of Formula (II- A), or a pharmaceutically acceptable (R4)msalt, a stereoisomer, or a deuterated form thereof,is (R )ms / (R4)m; m is 0 or 1; R4is halogen. In embodiments, R4is F, Cl or Br. In embodiments, (R4)m mR4is F. In some embodiments,(R>; m is 0 or 1; n ON=N-R6^-R6is 0; R2is or; R4is halogen; and R6is H or C1-3 alkyl. In some embodiments, m is 0. In some embodiments, m is 1 and R4is F. In some embodiments, R6is CH3.

[0093] In embodiments of the compound of Formula (II- A), or a pharmaceutically acceptable (R4)msalt, a stereoisomer, or a deuterated form thereof,is (R )mor ON=Ns,(R4)mN; m is 0 or 1; n is 0; R2is v,.; and R4is halogen.

[0094] In embodiments of the compound of Formula (II- A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2; R3is F, Cl, CH3, or CH3OH;O'R6(R5)P^ (R )m; m is 0 or 1; R4is halogen; R2is; p is 0, 1, 2 or 3; each R5is independently halogen, oxo, C1-6 alkyl, OC1-6 alkyl or CN; R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Attorney Docket No.: INMD-209 / 01WO 315953-4493(R3)n-F X / Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a further embodiment, nis 0, and H is. In a further embodiment, m is 1 and R4is halogen. In embodiments, R4is F, Cl or (R4)m FBr. In embodiments, R4is F. In embodiments,. In embodiments, (R4)m F, wherein the asterisk (*) represents the point of attachment toR2. In a further embodiment, R2is; p is 0; and R6is C1-6 alkyl. In yet even a further embodiment, R6is CH3.

[0095] A compound of Formula (II- A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0096] In one embodiment, the present disclosure provides a compound of Formula (II-B):(R3)n(II-B),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinn is 0, 1 or 2;m is 0, 1, 2, 3 or 4;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;ring B and ring C are each independently an aromatic ring optionally substituted with 1-3 group selected from R5or R6;X is CH2or NR6;W is N or CH;L is CH2, O, S(=O)2or NH;ring E is cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;p is 0, 1, 2 or 3;U and V are each independently CH2, C(=O), O or NR6;q and r are each independently 0, 1, 2 or 3, provided that q and r are not both 0;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R5is independently selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl, heterocyclyl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;each R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(C 1-6 alkyl), N(Ci-ealkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl.

[0097] In some embodiments of Formula (II-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2; and R3is F, Cl, CH3, or CH3OH. Ina further embodiment, nis 0, and

[0098] In embodiments of Formula (II-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1; R4is halogen. In a further embodiment,m is 0. In a further embodiment, m is 1. In embodiments,is embodiments, R4is halogen. In embodiments, R4is F, Cl or Br. In embodiments, R4is F. Inembodiments,!4)m. In embodiments,wherein the asterisk (*) represents the point of attachment to R2.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0099] In embodiments of Formula (II-B), or a pharmaceutically acceptable salt, a O'R6(R5)P^ I stereoisomer, or a deuterated form thereof, R2is; p is 0, 1, 2 or 3; each R5is independently halogen, oxo, C1-6 alkyl, OC1-6 alkyl or CN; R6is H, C1-6 alkyl, C1-6 alkylene- N(CI-6 alkyl)?, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a further embodiment, p is 0, 1, 2 or 3; each R5is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl, C1-6 alkylene- N(C1-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In yet a further embodiment, p is 0; and R6is C1-6 alkyl. In yet even a further embodiment, R6is CH3.

[0100] A compound of Formula (II-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0101] In embodiments of the compound of Formula (II-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1; R4is halogen. In embodiments, R4is F, Cl or Br. In embodiments, R4is F.

[0102] In embodiments of the compound of Formula (II-B), or a pharmaceutically acceptable O-R6salt, a stereoisomer, or a deuterated form thereof, mis 0 or 1; n is 0; R2is or N=NhkR6; R4is halogen; and R6is H or C1-3 alkyl. In some embodiments, m is 0. In some embodiments, m is 1 and R4is F. In some embodiments, R6is CH3.

[0103] In embodiments of the compound of Formula (II-B), or a pharmaceutically acceptable Osalt, a stereoisomer, or a deuterated form thereof, mis 0 or 1; n is 0; R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493N=N; and R4is halogen.

[0104] In embodiments of a compound of Formula (II), (II- A), or (II-B), or a pharmaceutically ON-R6 c )(R5)P- J M acceptable salt, a stereoisomer, or a deuterated form thereof, R2is or.ON=N A... A~R6, SAA~R6< R=)p-Q O-(R5)PIn embodiments, R2is, or — L-. In some embodiments of a compound of Formula (II), (II- A), or (II-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, p is 0 or 1. In some embodiments of the compounds of Formula (II), (II-A), or (II-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5is selected from halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl.

[0105] In some embodiments of a compound of Formula (II), (II-A), or (II-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6is H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl.

[0106] In another embodiment of a compound of Formula (II), (II-A), or (II-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,, R6is C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), or C1-6 alkylene-N(Ci-6 alkylene-O-C1-6 alkyl)(Ci-6 alkyl). In yet another embodiment of a compound of Formula (II), (II-A), or (II-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6is C1-6 alkyl. In some embodiments of the compounds of Formula (II), (II-A), or (II-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6is C1-3 alkyl. In a further embodiment, R6is CH3.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0107] In one embodiment, the present disclosure provides a compound of Formula (II-C):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein,n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;p is 0, 1, 2 or 3;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl or heterocyclyl; andR6is selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl.

[0108] In embodiments of the compound of Formula (II-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2; and R3is F, Cl, CH3, or CH3OH. In a further embodiment, n is 0.

[0109] In embodiments of Formula (II-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1; R4is halogen. In a further embodiment,m is 0. In a further embodiment, m is 1. In embodiments,embodiments, R4is halogen. In embodiments, R4is F, Cl or Br. In embodiments, R4is F. InAttorney Docket No.: INMD-209 / 01WO 315953-4493wherein the asterisk (*) represents the point of attachment to R2.

[0110] In embodiments of Formula (II-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, p is 0, 1, 2 or 3; each R5is independently halogen, oxo, Ci-6 alkyl or CN; and R6is H, Ci-6 alkyl, deuterated Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a further embodiment, p is 0. In a further embodiment, R5is independently F, CH3 or CN. In further embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In yet a further embodiment, R6is CH3.

[0111] A compound of Formula (II-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0112] In another embodiment, the present disclosure provides a compound of Formula (II-D),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein,Q is CH, CR5orN;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;p is 0, 1, 2 or 3;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R5is independently selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl or heterocyclyl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl.

[0113] In one embodiment of a compound of Formula (II-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5is halogen. In embodiments, R5is F. In embodiments, p is 0.

[0114] A compound of Formula (II-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0115] In another embodiment, the present disclosure provides a compound of Formula (II-D ),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein,Q is CH, CR5aor N;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;p is 0, 1, 2 or 3;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;Attorney Docket No.: INMD-209 / 01WO 315953-4493eachR5is independently halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl or heterocyclyl;R5ais halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHCi-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl or heterocyclyl; and R6is selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl.

[0116] In one embodiment of a compound of Formula (II-D ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5ais halogen. In embodiments, R5ais F.

[0117] In one embodiment of a compound of Formula (II-D) or (II-D ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Q is CH, CF, or N. In embodiments, Q is CH. In embodiments, Q is CF. In embodiments, Q is N.

[0118] In one embodiment of a compound of Formula (II-D) or (II-D ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Q is CH or N.

[0119] A compound of Formula (II-D ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0120] In another embodiment, the present disclosure provides a compound of Formula (II-E):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein,Ring A is polycyclic arylene, polycyclic heteroarylene or polycyclic heterocyclylene; R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S orAttorney Docket No.: INMD-209 / 01WO 315953-4493O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;R3is selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2 or NHC(O)CI-6 alkyl;R4is selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl |— L— (T)heteroaryl, or’ O, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andR6is selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

[0121] A compound of Formula (II-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (II), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0122] In one embodiment, the present disclosure provides a compound of Formula (III),Attorney Docket No.: INMD-209 / 01WO 315953-4493or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinRing A is arylene, heteroarylene or heterocyclylene;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6,each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl,|— L— (T)S(=O)2alkyl, heterocyclyl, heteroaryl, or« O, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-Attorney Docket No.: INMD-209 / 01WO 315953-44936 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), Ci-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

[0123] In some embodiments of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1 or 2; and each R3is independently F, Cl, CH3, or CH3OH.

[0124] In some embodiments of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1. In a further embodiment, R3is C1-6 alkyl. In yet a further embodiment, R3is methyl or ethyl. In even a further embodiment, R3is methyl.

[0125] In some embodiments of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0. In a further embodiment,(R3)nl£ N N N H H(n is 0). In another embodiment, H 0).

[0126] In some embodiments of a compound of Formula (III), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof,; m is 0 or 1; and R4is halogen.

[0127] In some embodiments of a compound of Formula (III), or a pharmaceutically acceptable (R4)msalt, a stereoisomer, or a deuterated form thereof, mis 0, and(R4)m. In a further embodiment,. In another embodiment,Attorney Docket No.: INMD-209 / 01WO 315953-4493(R4)mis. In a further embodiment,I AS H wherein the asterisk (*) represents the point of attachment to R2.

[0128] In some embodiments of a compound of Formula (III), or a pharmaceutically acceptable (R4)msalt, a stereoisomer, or a deuterated form thereof,(R )mor s / (R4)m; m is 1; and R4is halogen. In a further embodiment, R4is F, Cl or Br. In even (R4)ma further embodiment, R4is F. In one embodiment,. In a further (R4)membodiment,, wherein the asterisk (*) represents the point of attachment to R2.

[0129] In some embodiments of a compound of Formula (III), or a pharmaceutically acceptable OQ=N hkR6(R5)P— A(R5)P salt, a stereoisomer, or a deuterated form thereof, R2isO(R5)p IR6; p is 0, 1, 2 or 3; Q is N, CH, or CF; each R5is independently halogen, oxo, Ci-6 alkyl, OCi-6 alkyl or CN; and R6is H, Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a O OA'''R6(R5)P^'further embodiment, R2is; p is 0, 1, 2 or 3; each R5, if present, isAttorney Docket No.: INMD-209 / 01WO 315953-4493independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O- O'R6(R5)P^ I Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In yet a further embodiment, R2is p is 0; and R6is Ci-6 alkyl. In yet even a further embodiment, R6is CH3. In a further embodiment, n is 0.

[0130] In some embodiments of a compound of Formula (III), or a pharmaceutically acceptable Q=NIX>R6O-<R5)P salt, a stereoisomer, or a deuterated form thereof,, R2is; Q is N, CH, or CF; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In a further embodiment, Q is N, CH, or CF; p is 0, and R6is C1-6 alkyl. In a further embodiment, R6is CH3 or CH2CH3. In even a further embodiment, R6is CH3.

[0131] In some embodiments of a compound of Formula (III), or a pharmaceutically acceptable Q=N-(R5)Psalt, a stereoisomer, or a deuterated form thereof, R2is —I—; Q is N; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In a further embodiment, Q is N; p is 0, 1, or 2; each R5, if present, is independently halogen, CN, C1-6 alkyl, or OC1-6 alkyl; and R6is C1-6 alkyl. In yet a further embodiment, Q is N; p is 0; and R6is C1-6 alkyl. In even a further embodiment, R6is CH3 or CH2CH3. In yet even a further embodiment, R6is CH3. In a further embodiment, n is 0.

[0132] In some embodiments of a compound of Formula (III), or a pharmaceutically acceptable Q-NO-(R5)Psalt, a stereoisomer, or a deuterated form thereof, R2is; Q is CH; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In a further embodiment, Q is CH; p is 0, 1, or 2; each R5,Attorney Docket No.: INMD-209 / 01WO 315953-4493if present, is independently halogen, CN, Ci-6 alkyl, or OCi-6 alkyl; and R6is Ci-6 alkyl. In yet a further embodiment, Q is CH; p is 0; and R6is Ci-6 alkyl. In even a further embodiment, R6is CH3 or CH2CH3. In yet even a further embodiment, R6is CH3. In a further embodiment, n is 0.

[0133] In some embodiments of a compound of Formula (III), or a pharmaceutically acceptable Q=N-(R5)Psalt, a stereoisomer, or a deuterated form thereof, R2is; Q is CF; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In a further embodiment, Q is CF; p is 0, 1, or 2; each R5, if present, is independently halogen, CN, C1-6 alkyl, or OC1-6 alkyl; and R6is C1-6 alkyl. In yet a further embodiment, Q is CF; p is 0; and R6is C1-6 alkyl. In even a further embodiment, R6is CH3 or CH2CH3. In yet even a further embodiment, R6is CH3. In a further embodiment, n is 0.

[0134] In one embodiment of a compound of Formula (III), or a pharmaceutically acceptableA'^N-'A) (R^p I salt, a stereoisomer, or a deuterated form thereof, R2is R6; p is 1, 2 or 3; each R5is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl.

[0135] In another embodiment of a compound of Formula (III), or a pharmaceuticallyA^N-AD (R^)p I acceptable salt, a stereoisomer, or a deuterated form thereof,R2is R6; p is 0; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl.

[0136] In one embodiment of a compound of Formula (III), or a pharmaceutically acceptableA^N-AD (R5)p I salt, a stereoisomer, or a deuterated form thereof, R2is R6; p is 0; and R6is Ci-Attorney Docket No.: INMD-209 / 01WO 315953-44936 alkyl. In a further embodiment, R6is CH3. In a further embodiment, n is 0.

[0137] In embodiments of the compound of Formula (III), or a pharmaceutically acceptableR4, if present, is halogen; and R6is H or C1-3 alkyl. In some embodiments, m is 0. In some embodiments, m is 1 and R4is F. In some embodiments, R6is CH3. In embodiments,

[0138] In embodiments of the compound of Formula (III), or a pharmaceutically acceptableAttorney Docket No.: INMD-209 / 01WO 315953-4493halogen. In a further embodiment, m is 1 and R4is F.

[0139] In embodiments of the compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2; R3is F, Cl, CH3, or CH3OH;s / (R4)mor; m is 0 or 1; R4, if present, is halogen; R2is(R )P l6orR; p is 0, 1, 2 or 3; Q is N, CH, or CF; each R5, if present, is independently halogen, oxo, C1-6 alkyl, OC1-6 alkyl or CN; R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a further embodiment, n is 0. In yet a(R4)membodiments,is, wherein the asterisk (*) represents the point of attachment to R2.

[0140] In one embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, or 1; R3, if present, is F, Cl, CH3, orAttorney Docket No.: INMD-209 / 01WO 315953-4493CH3OH;In a further embodiment, m is 1 and (R4)mR4is F. In even a further embodiment, n is 0. In embodiments,A) — I is I1" I (R4)m F (R4)mIn embodiments, ~A) — I isI — A #' — ' — I In embodiments,A) — i is F, wherein the asterisk (*) represents the point of attachment to R2.

[0141] In yet another embodiment of a compound of Formula (III), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof,is 1 and R4is F. In a further embodiment, R2is or 3; Q is N, CH, or CF; each R5, if present, is independently halogen, oxo, Ci-6 alkyl, OCi-6 alkyl or CN; R6is H, Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In even a furtherQ=NFis, wherein the asterisk (*) represents the point of attachment to R2.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0142] In yet another embodiment of a compound of Formula (III), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof,Q=N KkR6 5 ^7-(R )P R4is F. In a further embodiment, R2is is N, CH, or CF; each R5, if present, is independently halogen, oxo, C1-6 alkyl, OC1-6 alkyl or CN; R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In even a further Q-Nembodiment, R2is Q is N and R6is C1-6 alkyl. In embodiments,, wherein the asterisk (*) represents the point of attachment to R2.

[0143] In yet another embodiment of a compound of Formula (III), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, R2is -J™-; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In yet a furtherembodiment, R2is; p is 0; and R6is C1-6 alkyl. In yet even a further (R4)membodiment, R6is CH3. In embodiments,. In embodiments,Attorney Docket No.: INMD-209 / 01WO 315953-44934 4(R )m. (R>isN. In embodiments, HA / H isN, wherein the asterisk (*) represents the point of attachment to R2. In further embodiments, m is 1 and R4is halogen. In embodiments, R4is F, Cl or Br. In embodiments, R4is F. In embodiments, (R4)m Fx(R4)m Fx|— / A ) — | | — / A j | | — z^A — I*' is ' — '. In embodiments, is ' — ', wherein the asterisk (*) represents the point of attachment to R2. In a further embodiment,

[0144] In yet another embodiment of a compound of Formula (III), or a pharmaceutically Q-N J^-R6acceptable salt, a stereoisomer, or a deuterated form thereof, R2is; Q is N, CH, or CF; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In a further embodiment, Q is N, CH, or CF; p is 0, and R6is C1-6 alkyl. In yet a further embodiment, Q is N; p is 0; and R6is C1-6 alkyl. In yet a further embodiment, Q is CH; p is 0; and R6is C1-6 alkyl. In yet a further embodiment, Q is CF; p is 0; and R6is C1-6 alkyl. In yet even a further embodiment, R6is CH3.represents the point of attachment to R2. In further embodiments, m is 1 and R4is halogen. Inembodiments, R4is F, Cl or Br. In embodiments, R4is F. In embodiments,represents the point of attachment to R2.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0145] In yet another embodiment of a compound of Formula (III), or a pharmaceuticallyO(R5)p I acceptable salt, a stereoisomer, or a deuterated form thereof, R2is R6; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a further embodiment, p is 0; and R6is C1-6 alkyl. In yet a further embodiment,(R 4 )m (R 4 )mR6is CH3. In embodiments,. In embodiments,is(R4)rn. In embodiments, is, wherein the asterisk (*) represents the point of attachment to R2. In further embodiments, m is 1 and R4is halogen. In (R4)membodiments, R4is F, Cl or Br. In embodiments, R4is F. In embodiments,is F (R4)m F. In embodiments,, wherein the asterisk (*) represents the point of attachment to R2.

[0146] In one embodiment, the present disclosure provides a compound of Formula (III- 1):(R3)nm(III-l),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinRing A is arylene, heteroarylene or heterocyclylene;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;Attorney Docket No.: INMD-209 / 01WO 315953-4493R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl,|— L— (T)S(=O)2alkyl, heterocyclyl, heteroaryl, or’, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

[0147] In one embodiment of a compound of Formula (III- 1 ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0148] A compound of Formula (III- 1), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0149] In yet another embodiment, the present disclosure provides a compound of Formula (III-2):H NN(III-2),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinRing A is arylene, heteroarylene or heterocyclylene;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl,L— ( )S(=O)2alkyl, heterocyclyl, heteroaryl, or5, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl,Attorney Docket No.: INMD-209 / 01WO 315953-4493alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

[0150] In one embodiment of a compound of Formula (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0.

[0151] A compound of Formula (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0152] In another embodiment of a compound of Formula (III), (III-l), or (III-2), or ahalogen; and R6is H or C1-3 alkyl. In one embodiment of a compound of Formula (III), (III- 1), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0. In another embodiment, m is 1 and R4is F. In even another embodiment of a compound of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6is CH3.

[0153] In another embodiment, the present disclosure provides a compound of Formula (III-A):Attorney Docket No.: INMD-209 / 01WO 315953-4493(R3)n4NH(R4)mR2(III-A),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein,n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6,each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl,|— L— (T)S(=O)2alkyl, heterocyclyl, heteroaryl, or’ O, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-Attorney Docket No.: INMD-209 / 01WO 315953-4493heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

[0154] In some embodiments of a compound of Formula (III- A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1 or 2; and each R3is independently F, Cl, CH3, or CH3OH.

[0155] In some embodiments of a compound of Formula (III- A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1. In a further embodiment, R3is C1-6 alkyl. In yet a further embodiment, R3is methyl or ethyl. In even a further embodiment, R3is methyl.

[0156] In some embodiments of a compound of Formula (III- A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0. In a further embodiment,(n is 0). In another embodiment,

[0157] In some embodiments of a compound of Formula (III- A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0.

[0158] In some embodiments of a compound of Formula (III- A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 1 and R4is halogen. In furtherattachment to R2.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0159] In some embodiments of a compound of Formula (III- A), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, R2isQ=N(R5)P p6; p is 0, 1, 2 or 3; Q is N, CH, or CF; each R, if present,5is independently halogen, oxo, Ci-6 alkyl, OCi-6 alkyl orCN; andR6isH, Ci-6 alkyl, Ci-6 alkylene- N(C1-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci- O'R6(R5)P^ I 6 alkyl) or heterocyclyl. In a further embodiment, R2is; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In yet a further embodiment,O-R6(R5)P4'R2is; p is 0; and R6is Ci-6 alkyl. In yet even a further embodiment, R6is CH3. In a further embodiment, n is 0.

[0160] In some embodiments of a compound of Formula (III- A), or a pharmaceutically Q-N ^X / ^'R6Q-(R5)P acceptable salt, a stereoisomer, or a deuterated form thereof, R2is; Q is N, CH, or CF; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In a further embodiment, Q is N, CH, or CF; p is 0, and R6is C1-6 alkyl. In a further embodiment, R6is CH3 or CH2CH3. In even a further embodiment, R6is CH3.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0161] In some embodiments of a compound of Formula (III- A), or a pharmaceutically Q=N J'VN'R6CJ1-(R5)P acceptable salt, a stereoisomer, or a deuterated form thereof, R2is —1—; Q is N; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In a further embodiment, Q is N; p is 0, 1, or 2; each R5if present, is independently halogen, CN, C1-6 alkyl, or OC1-6 alkyl; and R6is C1-6 alkyl. In yet a further embodiment, Q is N; p is 0; and R6is C1-6 alkyl. In even a further embodiment, R6is CH3 or CH2CH3. In yet even a further embodiment, R6is CH3. In a further embodiment, n is 0.

[0162] In some embodiments of a compound of Formula (III- A), or a pharmaceutically Q=N-(R5)P acceptable salt, a stereoisomer, or a deuterated form thereof, R2is; Q is CH; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In a further embodiment, Q is CH; p is 0, 1, or 2; each R5is independently halogen, CN, C1-6 alkyl, or OC1-6 alkyl; and R6is C1-6 alkyl. In yet a further embodiment, Q is CH; p is 0; and R6is C1-6 alkyl. In even a further embodiment, R6is CH3 or CH2CH3. In yet even a further embodiment, R6is CH3. In a further embodiment, n is 0.

[0163] In some embodiments of a compound of Formula (III- A), or a pharmaceutically Q=NOJ-fR^p acceptable salt, a stereoisomer, or a deuterated form thereof, R2is; Q is CF; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In a further embodiment, Q is CF; p is 0, 1, or 2; each R5is independently halogen, CN, C1-6 alkyl, or OC1-6 alkyl; and R6is C1-6 alkyl. In yet a further embodiment, Q is CF; p is 0; and R6is C1-6 alkyl. In even a further embodiment, R6is CH3 or CH2CH3. In yet even a further embodiment, R6is CH3. In a further embodiment, n is 0.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0164] In one embodiment of a compound of Formula (III- A), or a pharmaceutically acceptableA^N'AD(R^p Isalt, a stereoisomer, or a deuterated form thereof,, R2is R6; p isl, 2 or 3; each R5is independently halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl.

[0165] In another embodiment of a compound of Formula (III- A), or a pharmaceuticallyA^N^O (R^)p I acceptable salt, a stereoisomer, or a deuterated form thereof, R2is R6; p is 0; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl.

[0166] In one embodiment of a compound of Formula (III- A), or a pharmaceutically acceptable L A / ^ 1N^ 1O (R5)p I salt, a stereoisomer, or a deuterated form thereof, R2is R6; p is 0; and R6is Ci- 6 alkyl. In a further embodiment, R6is CH3. In a further embodiment, n is 0.

[0167] In embodiments of the compound of Formula (III- A), or a pharmaceutically acceptable OQ=N / , N^R6 >( N-R6(RVY L^(R5)P salt, a stereoisomer, or a deuterated form thereof, R2is or; p is 0, 1, 2 or 3; Q is N, CH, or CF; each R5, if present, is independently halogen, oxo, C1-6 alkyl, OC1-6 alkyl or CN; R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a O AJ^ AR6(R5)P^Jfurther embodiment, R2is; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl,Attorney Docket No.: INMD-209 / 01WO 315953-4493Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-C1-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In yet a further embodiment, R2is p is 0; and R6is C1-6 alkyl. In yet even a further embodiment, R6is CH3. In another embodiment, Q-N( XR6,7-(R5)P; Q is N, CH, or CF; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In a further embodiment, Q is N, CH, or CF; p is 0, and R6is C1-6 alkyl. In yet a further embodiment, Q is N; p is 0; and R6is C1-6 alkyl. In yet even a further embodiment, R6is CH3. In a further embodiment, n is 0.

[0168] In embodiments of the compound of Formula (III- A), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, mis 0 or 1; n is 0; R2is N=N'R6N^OR4is halogen; and R6is H or C1-3 alkyl. In some embodiments, m is 0. In some embodiments, m is 1 and R4is F. In some embodiments, R6is CH3. In a further embodiment, n is 0.

[0169] In embodiments of the compound of Formula (III- A), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, mis 0 or 1; n is 0; R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493and R4is halogen. In a further embodiment, m is 1 and R4is F. In a further embodiment, n is 0.

[0170] In embodiments of the compound of Formula (III- A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2; R3, if present, is independently OQ=N / KLR6 N-R6(R5)pni jf L^-(R5)PF, Cl, CH3, or CH3OH; m is 0 or 1; R4is halogen; R2is or — L-; p is 0, 1, 2 or 3; Q is N, CH, or CF; each R5, if present, is independently halogen, oxo, C1-6 alkyl, OC1-6 alkyl or CN; and R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In afurther embodiment, n is 0. In yet a further embodiment,another embodiment,. In a further embodiment, m is 0. In anotherembodiment, m is 1. In embodiments,halogen. In embodiments, R4is F, Cl or Br. In a further embodiment, R4is F. In embodiments,wherein the asterisk (*) represents the point of attachment to R2. In a further embodiment, R2is“J—; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6Attorney Docket No.: INMD-209 / 01WO 315953-4493alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or OR6(R5)P< J heterocyclyl. In yet a further embodiment, R2is; p is 0; and R6is Ci-6 alkyl.Q=NO-(R5)P In yet even a further embodiment, R6is CH3. In another embodiment, R2is; Q is N, CH, or CF; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In a further embodiment, Q is N, CH, or CF; p is 0, and R6is C1-6 alkyl. In yet a further embodiment, Q is N; p is 0; and R6is C1-6 alkyl. In yet a further embodiment, R6is CH3.

[0171] A compound of Formula (III-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0172] In even another embodiment, the present disclosure provides a compound of Formula (III-B):(R3)n4>~i NHOR65(R )p(III-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinn is 0, 1 or 2;m is 0, 1, 2, 3 or 4;p is 0, 1, 2 or 3;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R5is independently selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl or heterocyclyl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl.

[0173] In some embodiments of a compound of Formula (III-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1 or 2; and each R3is independently F, Cl, CH3, or CH3OH.

[0174] In some embodiments of a compound of Formula (III-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1. In a further embodiment, R3is C1-6 alkyl. In yet a further embodiment, R3is methyl or ethyl. In even a further embodiment, R3is methyl.

[0175] In some embodiments of a compound of Formula (III-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0. In a further embodiment,(RW N N N N H H H H(n is 0). In yet a further embodiment, (n is 0).

[0176] In some embodiments of a compound of Formula (III-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0.

[0177] In some embodiments of a compound of Formula (III-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 1. In further embodiments,In further embodiments, R4is halogen. In even further embodiments, R4is F, Cl or Br. In yet further embodiments, R4is F. In one embodiment,In a further embodiment, wherein the asterisk (*) represents the point of attachment to R2.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0178] In some embodiments of a compound of Formula (III-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, Ci-6 alkyl or CN; and R6is H, Ci-6 alkyl, deuterated Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a further embodiment, p is 0. In a further embodiment, R5is independently F, CH3 or CN. In further embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In yet a further embodiment, R6is CH3.

[0179] In embodiments of a compound of Formula (III-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2; R3, if present, is each independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, C1-6 alkyl or CN; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl.

[0180] A compound of Formula (III-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0181] In yet another embodiment, the present disclosure provides a compound of Formula (III-C):H N N N HR6>°(R )P(III-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the definition of R3, R4, R5, R6, n, m and p is as defined in Formula (III-B).

[0182] In some embodiments of a compound of Formula (III-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1, or 2; and each R3is independently F, Cl, CH3, or CH3OH.

[0183] In some embodiments of a compound of Formula (III-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1. In a further embodiment, R3is C1-6 alkyl. In yet a further embodiment, R3is methyl or ethyl. In even a further embodiment, R3is methyl.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0184] In some embodiments of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0.

[0185] In some embodiments of a compound of Formula (III-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0.

[0186] In some embodiments of a compound of Formula (III-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 1. In embodiments,(*) represents the point of attachment to R2.

[0187] In embodiments of a compound of Formula (III-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, Ci-6 alkyl or CN; and R6is H, Ci-6 alkyl, deuterated Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a further embodiment, p is 0. In a further embodiment, R5is independently F, CH3 or CN. In further embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In yet a further embodiment, R6is CH3.

[0188] In embodiments of a compound of Formula (III-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2; R3, if present, is each independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, C1-6 alkyl or CN; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl.

[0189] A compound of Formula (III-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0190] In one embodiment, the present disclosure provides a compound of Formula (III-D):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the definition of R3, R4, R5, R6, n, m and p is as defined in Formula (III-B).

[0191] In some embodiments of a compound of Formula (III-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1, or 2; and R3is F, Cl, CH3, or CH3OH.

[0192] In some embodiments of a compound of Formula (III-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1. In a further embodiment, R3is C1-6 alkyl. In yet a further embodiment, R3is methyl or ethyl. In even a further embodiment, R3is methyl.

[0193] In some embodiments of a compound of Formula (III-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0.

[0194] In some embodiments of a compound of Formula (III-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0.

[0195] In some embodiments of a compound of Formula (III-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 1. In a further embodiment,R4 / | \\ n |(R)mis?— J. In a further embodiment, R4is halogen. In yet a further embodiment, R4is F, Cl or Br. In even a further embodiment, R4is F. In one embodiment,wherein the asterisk (*) represents the point of attachment to R2.

[0196] In embodiments of a compound of Formula (III-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, C1-6 alkyl or CN; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-Attorney Docket No.: INMD-209 / 01WO 315953-44936 alkyl)(C 1-6 alkyl) or heterocyclyl. In a further embodiment, p is 0. In a further embodiment, R5is independently F, CH3 or CN. In further embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In yet a further embodiment, R6is CH3.

[0197] In embodiments of a compound of Formula (III-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2; R3, if present, is each independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, C1-6 alkyl or CN; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl.

[0198] A compound of Formula (III-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0199] In yet even another embodiment, the present disclosure provides a compound of Formula (III-E):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinRing A is polycyclic arylene, polycyclic heteroarylene or polycyclic heterocyclylene; R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl,L—S(=O)2alkyl, heterocyclyl, heteroaryl, or’ O, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

[0200] A compound of Formula (III-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0201] In yet another embodiment, the present disclosure provides a compound of Formula (III-F):(R3)n H NN N HR6hi(III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Q is CH, CR5or N, and R3, R4, R5, R6, n, m and p are as defined in Formula (III-E).Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0202] In one embodiment of a compound of Formula (III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5is halogen. In embodiments, R5is F. In some embodiments, p is 0.

[0203] In some embodiments of a compound of Formula (III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1 or 2; and each R3is independently F, Cl, CH3, or CH3OH.

[0204] In some embodiments of a compound of Formula (III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1. In a further embodiment, R3is C1-6 alkyl. In yet a further embodiment, R3is methyl or ethyl. In even a further embodiment, R3is methyl.

[0205] In some embodiments of a compound of Formula (III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0. In a further embodiment,N(R3)np HIS (n is 0). In yet a further embodiment,H> is(n is 0).

[0206] In one embodiment of a compound of Formula (III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1; and R4, if present, is halogen.

[0207] In some embodiments of a compound of Formula (III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0.

[0208] In some embodiments of a compound of Formula (III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 1. In a further embodiment,(R>. In a further embodiment, R4is halogen. In yet a further embodiment, R4is F, Cl or Br. In even a further embodiments, R4is F. In one embodiment,. In a further embodiment, wherein the asterisk (*) represents the point of attachment to R2.

[0209] In one embodiment of a compound of Formula (III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, Ci-6 alkyl or CN; Q is CH, CF, or N; and R6is H, Ci-6 alkyl,Attorney Docket No.: INMD-209 / 01WO 315953-4493deuterated Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a further embodiment, p is 0. In a further embodiment, R5is independently F, CH3 or CN. In further embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(CI-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In yet a further embodiment, R6is CH3.

[0210] In one embodiment of a compound of Formula (III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Q is CH, CF, or N; n is 0, 1, or 2; R3, if present, is independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, C1-6 alkyl or CN; and R6is H, Ci-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In some embodiments, Q is N; n is 0, 1, or 2; R3, if present, is each independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, C1-6 alkyl or CN; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In some embodiments, Q is N; n is 0, 1, or 2; R3, if present, is independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0; and R6is H or C1-6 alkyl. In some embodiments, R6is H or C1-3 alkyl. In yet a further embodiment, R6is CH3.

[0211] In one embodiment of a compound of Formula (III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2; R3, if present, is each independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; Q is CH, CF, or N; p is 0, 1, 2, or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In a further embodiment, n is 0. In yet. In a further embodiment, m is 0. In another embodiment, m is 1. In a furtherIn a further embodiment, R4is halogen. In yet a further embodiment, R4is F, Cl or Br. In even a further embodiment, R4is F. In oneAttorney Docket No.: INMD-209 / 01WO 315953-4493embodiment,(R)mIn a further embodiment,(R)mF, wherein the asterisk (*) represents the point of attachment to R2. In some embodiments, Q is N; p is 0, and R6is Ci-6 alkyl. In a further embodiment, R6is CH3.

[0212] A compound of Formula (III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0213] In yet another embodiment, the present disclosure provides a compound of Formula (III-F ):(R3)n H NN NH(III-F ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:Q is CH, CR5aor N; andR5ais halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHCi-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl heteroaryl,orL—, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5aare optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andR3, R4, R6, n, m and p are as defined in formula (III-E).

[0214] In one embodiment of a compound of Formula (III-F´), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5ais halogen. In embodiments, R5ais F.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0215] In one embodiment of a compound of Formula (III-F) or (III-F '), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Q is CH, CF, or N. In a further embodiment, Q is CH. In another embodiment, Q is CF. In still another embodiment, Q is N.

[0216] In embodiments of the compound of Formula (III-F) or (III-F´), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;p is 0, 1, 2 or 3;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl or heterocyclyl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl.

[0217] In some embodiments of a compound of Formula (III-F´), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1 or 2; and R3is F, Cl, CH3, or CH3OH.

[0218] In some embodiments of a compound of Formula (III-F´), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1. In a further embodiment, R3is C1-6 alkyl. In yet a further embodiment, R3is methyl or ethyl. In even a further embodiment, R3is methyl.

[0219] In some embodiments of a compound of Formula (III-F´), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0. In a further embodiment,(RW N N N N H H H H(n is 0). In yet another embodiment, (n is 0).Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0220] In one embodiment of a compound of Formula (III-F ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1; R4, if present, is halogen.

[0221] In some embodiments of a compound of Formula (III-F ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0.

[0222] In some embodiments of a compound of Formula (III-F ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 1. In a further embodiment,R4>4 / I \\ n |(R)mis ’ — J. In a further embodiment, R4is halogen. In yet a further embodiment, R4is F, Cl or Br. In even a further embodiment, R4is F. In one embodiment,wherein the asterisk (*) represents the point of attachment to R2.

[0223] In one embodiment of a compound of Formula (III-F ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, Ci-6 alkyl or CN; Q is CH, CF, or N; and R6is H, Ci-6 alkyl, deuterated Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a further embodiment, p is 0. In a further embodiment, R5is independently F, CH3 or CN. In further embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(CI-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In yet a further embodiment, R6is CH3.

[0224] In one embodiment of a compound of Formula (III-F ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Q is CH, CF, or N; n is 0, 1, or 2; R3, if present, is each independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, C1-6 alkyl or CN; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In some embodiments, Q is N; n is 0, 1, or 2; R3, if present, is each independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, C1-6 alkyl or CN; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-Attorney Docket No.: INMD-209 / 01WO 315953-44936 alkyl) or heterocyclyl. In some embodiments, Q is N; n is 0, 1, or 2; R3, if present, is each independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0; and R6is H or C1-6 alkyl. In some embodiments, R6is H or C1-3 alkyl. In yet a further embodiment, R6is CH3.

[0225] A compound of Formula (III-F '), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0226] In still another embodiment, the present disclosure provides a compound of Formula (IILG):H N N NHs / (R4)'^R2N(IILG),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinn is 0, 1 or 2;m is 0 or 1;R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;R4is selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH,Attorney Docket No.: INMD-209 / 01WO 315953-4493COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6|— L— (T)alkyl, S(=0)2 alkyl, heterocyclyl heteroaryl, or’, wherein L is Ci-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OCi-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(CI-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(CI-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

[0227] In some embodiments of a compound of Formula (III-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1 or 2; and R3is F, Cl, CH3, or CH3OH.

[0228] In some embodiments of a compound of Formula (III-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1. In a further embodiment, R3is C1-6 alkyl. In yet a further embodiment, R3is methyl or ethyl. In even a further embodiment, R3is methyl.

[0229] In some embodiments of a compound of Formula (III-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0. In a further embodiment,0).

[0230] In some embodiments of a compound of Formula (III-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1 and R4, if present, is halogen or C1-6 alkyl.

[0231] In some embodiments of a compound of Formula (III-G), or a pharmaceutically Z s / (R4)macceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 andAttorney Docket No.: INMD-209 / 01WO 315953-4493. In a further embodiment, is, wherein the asterisk (*) represents the point of attachment to R2.

[0232] In some embodiments of a compound of Formula (III-G), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, R2is Q-N^4 n-(R55)PL / JI L\ (R^P ', or R6; p is 0, 1, 2 or 3; Q is N, CH, or CF; each R5, if present, is independently halogen, oxo, Ci-6 alkyl, OCi-6 alkyl or CN; R6is H, Ci-6 alkyl, Ci-6 alkylene- N(C1-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci- O'R6(R5)P^ I 6 alkyl) or heterocyclyl. In a further embodiment, R2is; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In yet a further embodiment,OR6(R5)P< J R2is; p is 0; and R6is C1-6 alkyl. In yet even a further embodiment, R6is Q=N JLZ^-R6O-(R5)PCH3. In another embodiment, R2is; Q is N, CH, or CF; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl; and R6is C1-6 alkyl or heterocyclyl. In yet a further embodiment, Q is N, CH, or CF; p is 0, and R6is Ci-6 alkyl. In yet a further embodiment, Q is N; p is 0; and R6is C1-6 alkyl. In yet a furtherAttorney Docket No.: INMD-209 / 01WO 315953-4493embodiment, Q is CH; p is 0; and R6is Ci-6 alkyl. In yet a further embodiment, Q is CF; p is 0; and R6is Ci-6 alkyl. In yet even a further embodiment, R6is CH3. In a further embodiment,N; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, Ci- 6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In yet a further embodiment, p is 0; and R6is C1-6 alkyl. In yet a further embodiment, R6is CH3.

[0233] In some embodiments of a compound of Formula (III-G), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof,R2is Q=NR65)P; p is 0, 1, 2 or 3; Q is N, CH, or CF; each R5, if present, is independently halogen, oxo, C1-6 alkyl, OC1-6 alkyl or CN; R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) orheterocyclyl. In a further embodiment, R2is; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl; and R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In yet a further embodiment, R2is; p is 0; and R6is C1-6 alkyl. In yet even a further embodiment, R6is CH3.Attorney Docket No.: INMD-209 / 01WO 315953-4493Q=NQ-(R5)PIn another embodiment, R2is; Q is N, CH, or CF; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl; and R6is Ci-6 alkyl or heterocyclyl. In a further embodiment, Q is N, CH, or CF; p is 0, and R6is C1-6 alkyl. In yet a further embodiment, Q is N; p is 0; and R6is C1-6 alkyl. In yet even a further embodiment, R6is CH3.

[0234] In embodiments of the compound of Formula (III-G), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, mis 0 or 1; n is 0; R2isR4, if present, is halogen; and R6is H or C1-3 alkyl. In some embodiments, m is 0. In some embodiments, m is 1 and R4is F. In some embodiments, R6is CH3.

[0235] In embodiments of the compound of Formula (III-G), or a pharmaceutically acceptable r-Nu salt, a stereoisomer, or a deuterated form thereof, mis 0 or 1; n is 0; R2is ON=N QJCJ cX? U,, or; and R4, if present, is halogen. In a further embodiment, m is 0. In another embodiment, m is 1 and R4is F.

[0236] A compound of Formula (III-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0237] In one embodiment, the present disclosure provides a compound of Formula (III-H):Attorney Docket No.: INMD-209 / 01WO 315953-4493or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R3, R4, R5, R6, n, and m are as defined in Formula (III-G), and p is 0, 1, 2, or 3.

[0238] In embodiments of the compound of Formula (III-H), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,n is 0, 1 or 2;m is 0 or 1;p is 0, 1, 2 or 3;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;R4is selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl or heterocyclyl; andR6is selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl.

[0239] A compound of Formula (III-H), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0240] In yet still another embodiment, the present disclosure provides a compound of Formula (III-I):Attorney Docket No.: INMD-209 / 01WO 315953-4493or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Q is CH, CR5or N, and R3, R4, R5, R6, n, and m are as defined in formula (III-G), and p is 0, 1, 2, or 3.

[0241] In one embodiment of a compound of Formula (III-I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5is halogen. In embodiments, R5is F. In embodiments, p is 0.

[0242] In one embodiment of a compound of Formula (III-I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5is halogen. In embodiments, R5is F. In some embodiments, p is 0.

[0243] In some embodiments of a compound of Formula (III-I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1 or 2; and R3is F, Cl, CH3, or CH3OH.

[0244] In some embodiments of a compound of Formula (III-I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 1. In a further embodiment, R3is C1-6 alkyl. In yet a further embodiment, R3is methyl or ethyl. In even a further embodiment, R3is methyl.

[0245] In some embodiments of a compound of Formula (III-I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0. In a further embodiment,(n is 0). In another embodiment,

[0246] In one embodiment of a compound of Formula (III-I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 or 1; and R4, if present, is halogen or C1-6 alkyl.

[0247] In some embodiments of a compound of Formula (III-I), or a pharmaceutically Z s / (R4)macceptable salt, a stereoisomer, or a deuterated form thereof, m is 0 and RAttorney Docket No.: INMD-209 / 01WO 315953-4493wherein the asterisk (*) represents the point of attachment to R2.

[0248] In one embodiment of a compound of Formula (III-I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, Ci-6 alkyl or CN; Q is CH, CF, or N; and R6is H, Ci-6 alkyl, deuterated Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In a further embodiment, p is 0. In a further embodiment, R5is independently F, CH3 or CN. In further embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(CI-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In yet a further embodiment, R6is CH3.

[0249] In one embodiment of a compound of Formula (III-I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Q is CH, CF, or N; n is 0, 1, or 2; R3, if present, is independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, C1-6 alkyl or CN; and R6is H, Ci-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In some embodiments, Q is N; n is 0, 1, or 2; R3, if present, is independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, C1-6 alkyl or CN; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In some embodiments, Q is N; n is 0, 1, or 2; R3, if present, is independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4is halogen; p is 0; and R6is H or C1-6 alkyl. In some embodiments, m is 0. In some embodiments, R6is H or C1-3 alkyl. In yet a further embodiment, R6is CH3. In some embodiments, Q is CH; n is 0, 1, or 2; R3, if present, is independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0, 1, 2 or 3; each R5, if present, is independently halogen, oxo, C1-6 alkyl or CN; and R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-C1-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In some embodiments, Q is N; n is 0, 1, or 2; R3, if present, is independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4is halogen; p is 0; and R6is H or C1-6 alkyl. In some embodiments, m is 0. In some embodiments, R6is H or C1-3 alkyl. In yet a further embodiment, R6is CH3. In some embodiments, Q is CF; n is 0, 1, or 2; R3, if present, is independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4, if present, is halogen; p is 0, 1, 2 or 3;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R5, if present, is independently halogen, oxo, Ci-6 alkyl or CN; and R6is H, Ci-6 alkyl, deuterated Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In some embodiments, Q is N; n is 0, 1, or 2; R3, if present, is independently F, Cl, CH3, or CH3OH; m is 0 or 1; R4is halogen; p is 0; and R6is H or C1-6 alkyl. In some embodiments, m is 0. In some embodiments, R6is H or C1-3 alkyl. In yet a further embodiment, R6is CH3.

[0250] A compound of Formula (III-I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0251] In yet still another embodiment, the present disclosure provides a compound of Formula (III-I ):(III-I ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:Q is CH, CR5aor N;R5ais halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHCi-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl heteroaryl, |— L— (E)or’, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5aare optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;p is 0, 1, 2, or 3; andR3, R4, R6, n, and m are as defined in Formula (III-G).

[0252] In one embodiment of a compound of Formula (III-I ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5ais halogen. In embodiments, R5ais F.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0253] In one embodiment of a compound of Formula (III-I) or (III-I'), Q is CH, CF, or N. In a further embodiment, Q is CH. In another embodiment, Q is CF. In still another embodiment, Q is N.

[0254] In embodiments of the compound of Formula (III-I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,n is 0, 1 or 2;m is 0 or 1;p is 0, 1, 2 or 3;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;R4is selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl or heterocyclyl; andR6is selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl.

[0255] A compound of Formula (III-I ), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (III), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0256] In one embodiment, the present disclosure provides a compound of Formula (lb):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein,Y1is -CH2-CH2-, -CH2-CH2CH2-, -CH2CH2NH-, -NHCH2CH2-, -CH2O-, -OCH2-, -CH2CH2O- or -OCH2CH2-;Attorney Docket No.: INMD-209 / 01WO 315953-4493Y2is -CH2- or -CH2-CH2-;Y3is absent, -NH-, -CH2-, -CH2-NH- or -NH-CH2-;Y4is absent, -CH2- or -O-;provided thatis notorRing A is arylene, heteroarylene or heterocyclylene;n is 0, 1 or 2;R3is selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(CI-6 alkyl)2or NHC(O)CI-6 alkyl;m is 0, 1, 2, or 3;R4is selected from halogen, -OH, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, -NH2, -NHC1-6 alkyl, -N(C1-6 alkyl)2, Ci-4 alkylene-NH-Ci-6 alkyl or Ci-4alkylene-N(Ci-6 alkyl)2;R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclylheteroaryl, or’ kZL / , wherein L is CH2, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andR6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6Attorney Docket No.: INMD-209 / 01WO 315953-4493alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), Ci-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH;wherein the compound is not a compound disclosed in patent application publication no. CN114106005.

[0257] A compound of Formula (lb), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0258] In one embodiment, the present disclosure provides a compound of Formula (Ib-A):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinY1is -CH2-CH2-, -CH2-CH2CH2-, -CH2CH2NH-, -NHCH2CH2-, -CH2O-, -OCH2-, -CH2CH2O- or -OCH2CH2-;Y2is -CH2- or -CH2-CH2-;Y3is absent, -NH-, -CH2-, -CH2-NH- or -NH-CH2-;Y4is absent, -CH2- or -O-;L_Y2Y4\Y3^yprovided that' is notorn is 0, 1 or 2;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;m is 0, 1, 2, or 3;each R4is independently selected from halogen, -OH, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, -NH2, -NHC1-6 alkyl, -N(C1-6 alkyl)2, Ci-4 alkylene-NH-Ci-6 alkyl or Ci-4alkylene-N(Ci-6 alkyl)2;Attorney Docket No.: INMD-209 / 01WO 315953-4493R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;each R5is independently selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl,I— 1__S(=O)2alkyl, heterocyclyl, heteroaryl, or ’ O, wherein L is CH2, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH;wherein the compound is not a compound disclosed in patent application publication no. CN114106005.

[0259] A compound of Formula (Ib-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0260] In yet another embodiment, the present disclosure provides a compound of Formula (Ib-B):Attorney Docket No.: INMD-209 / 01WO 315953-4493or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinY1is -CH2-CH2-, -CH2-CH2CH2-, -CH2CH2NH-, -NHCH2CH2-, -CH2O-, -OCH2-, -CH2CH2O- or -OCH2CH2-;Y2is -CH2- or -CH2-CH2-;Y3is absent, -NH-, -CH2-, -CH2-NH- or -NH-CH2-;Y4is absent, -CH2- or -O-;n is 0, 1 or 2;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;m is 0, 1, 2, or 3;each R4is independently selected from halogen, -OH, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, -NH2, -NHC1-6 alkyl, -N(C1-6 alkyl)2, Ci-4 alkylene-NH-Ci-6 alkyl or Ci-4alkylene-N(Ci-6 alkyl)2;each R5is independently selected from halogen, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl or heterocyclyl;p is 0, 1, 2, or 3; andR6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl;Attorney Docket No.: INMD-209 / 01WO 315953-4493wherein the compound is not a compound disclosed in patent application publication no. CN114106005.

[0261] A compound of Formula (Ib-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0262] The compound of Formula (lb), (Ib-A) or (Ib-B) is not

[0263] In embodiments of the compound of Formula (lb), (Ib-A) or (Ib-B), or apharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,' is

[0264] In embodiments of the compound of Formula (lb), (Ib-A) or (Ib-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Y4is absent or -CH2-.

[0265] In embodiments of the compound of Formula (lb), (Ib-A) or (Ib-B), or apharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,' isAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0266] In another embodiment, the present disclosure provides a compound of Formula (Ib-C):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein,Y1is -CH2-CH2-, -CH2-CH2CH2-, -CH2CH2NH-, -NHCH2CH2-, -CH2O-, -OCH2-, - CH2CH2O- or -OCH2CH2-;Y2is -CH2- or -CH2-CH2-;Y3is absent, -NH-, -CH2-, -CH2-NH- or -NH-CH2-;Y4is absent, -CH2- or -O-;Ring A is polycyclic arylene, polycyclic heteroarylene or polycyclic heterocyclylene; n is 0, 1 or 2;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;m is 0, 1, 2, or 3;each R4is independently selected from halogen, -OH, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, -NH2, -NHC1-6 alkyl, -N(C1-6 alkyl)2, Ci-4 alkylene-NH-Ci-6 alkyl or Ci-4alkylene-N(Ci-6 alkyl)2;Attorney Docket No.: INMD-209 / 01WO 315953-4493R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;each R5is independently selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl,I— 1__S(=O)2alkyl, heterocyclyl, heteroaryl, or ’ O, wherein L is CH2, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

[0267] A compound of Formula (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0268] In another embodiment, the present disclosure provides a compound of Formula (Ic):H N N NH(RAttorney Docket No.: INMD-209 / 01WO 315953-4493or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:Ring A is arylene, heteroarylene or heterocyclylene;m is 0, 1, 2 or 3;n is 0, 1 or 2;R3is selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2 or NHC(O)CI-6 alkyl;Attorney Docket No.: INMD-209 / 01WO 315953-4493m is 0, 1, 2 or 3;p is 0, 1, 2 or 3;R4and R4aare each independently selected from halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl, heterocyclyl heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;R6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl;wherein the compound is not a compound disclosed in one or more of the following patent application publications: WO 2024094208, WO 2022053019, WO 2022053019, CNAttorney Docket No.: INMD-209 / 01WO 315953-4493114106005, US 20180125865, WO 2016139355, WO 2016038007, WO 2016016242, WO 2015032943, WO 2015032942, WO 2014140078, WO 2014140075, WO 2014140091, WO 2013041497, or WO 2012119941, the entirety of each of which are incorporated herein by reference.

[0269] A compound of Formula (Ic), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0270] In the compounds of Formula (Ic), or a pharmaceutically acceptable salt or a deuterated

[0271] In the compounds of Formula (Ic), or a pharmaceutically acceptable salt or a deuteratedAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0272] In the compounds of Formula (Ic), or a pharmaceutically acceptable salt or a deuterated (R4)mform thereof, whenis, wherein the asterisk (*) represents the point, wherein R6is C1-6 alkyl or heterocyclyl.

[0273] In the compounds of Formula (Ic), or a pharmaceutically acceptable salt or a deuteratedform thereof, when

[0274] In one embodiment, the present disclosure provides a compound of Formula (Ic-A):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinn is 0, 1 or 2;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;Attorney Docket No.: INMD-209 / 01WO 315953-4493m is 0, 1, 2 or 3;p is 0, 1, 2 or 3;R4and R4aare each independently selected from H, halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;R6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6Attorney Docket No.: INMD-209 / 01WO 315953-4493alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), Ci-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl;wherein the compound is not a compound disclosed in one or more of the following patent application publications: WO 2024094208, WO 2022053019, WO 2022053019, CN 114106005, US 20180125865, WO 2016139355, WO 2016038007, WO 2016016242, WO 2015032943, WO 2015032942, WO 2014140078, WO 2014140075, WO 2014140091, WO 2013041497, or WO 2012119941, the entirety of each of which are incorporated herein by reference.

[0275] A compound of Formula (Ic-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0276] In one embodiment, the present disclosure provides a compound of Formula (Ic-B):(R5)P(Ic-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, whereinn is 0, 1 or 2;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;m is 0, 1, 2 or 3;p is 0, 1, 2 or 3;each R4is independently selected from H, halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R5is independently selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, heterocyclyl or heteroaryl; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl;wherein the compound is not a compound disclosed in one or more of the following patent application publications: WO 2024094208, WO 2022053019, WO 2022053019, CN 114106005, US 20180125865, WO 2016139355, WO 2016038007, WO 2016016242, WO 2015032943, WO 2015032942, WO 2014140078, WO 2014140075, WO 2014140091, WO 2013041497, or WO 2012119941, the entirety of each of which are incorporated herein by reference.

[0277] A compound of Formula (Ic-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0278] In one embodiment, the present disclosure provides a compound of Formula (Ic-C):;p(Ic-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein,n is 0, 1 or 2;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;m is 0, 1, 2 or 3;p is 0, 1, 2 or 3;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;Attorney Docket No.: INMD-209 / 01WO 315953-4493each R5is independently selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl or heterocyclyl; andR6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl;wherein the compound is not a compound disclosed in one or more of the following patent application publications: WO 2024094208, WO 2022053019, WO 2022053019, CN 114106005, US 20180125865, WO 2016139355, WO 2016038007, WO 2016016242, WO 2015032943, WO 2015032942, WO 2014140078, WO 2014140075, WO 2014140091, WO 2013041497, or WO 2012119941, the entirety of each of which are incorporated herein by reference.

[0279] A compound of Formula (Ic-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0280] In one embodiment, the present disclosure provides a compound of Formula (Ic-D):H N N NH(R‘R2(Ic-D),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:Ring A is polycyclic arylene, polycyclic heteroarylene or polycyclic heterocyclylene; R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;Attorney Docket No.: INMD-209 / 01WO 315953-4493or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;each R3is independently selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl,|_ i_— (E?)S(=O)2alkyl, heterocyclyl, heteroaryl, or’ ' — ', wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH;wherein the compound is not a compound disclosed in one or more of the following patent application publications: WO 2024094208, WO 2022053019, WO 2022053019, CN 114106005, US 20180125865, WO 2016139355, WO 2016038007, WO 2016016242, WO 2015032943, WO 2015032942, WO 2014140078, WO 2014140075, WO 2014140091, WO 2013041497, or WO 2012119941, the entirety of each of which are incorporated herein by reference.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0281] A compound of Formula (Ic-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0282] In embodiments, the compound of Formula (Ic) or (Ic-D), or a pharmaceuticallypharmaceutically acceptable salt or a deuterated form thereof.

[0283] The compound of (Ic) or (Ic-D), or a pharmaceutically acceptable salt or a deuteratedAttorney Docket No.: INMD-209 / 01WO 315953-4493or a pharmaceutically acceptable salt or a deuterated form thereof.

[0284] In another embodiment, the present disclosure provides a compound of Formula (Ic-E):(Ic-E),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:Ring A is polycyclic arylene, polycyclic heteroarylene or polycyclic heterocyclylene;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;ring B and ring C are each independently an aromatic ring optionally substituted with 1-3 group selected from R5or R6;X is CH2or NR6;W is N or CH;L is CH2, O, S(=O)2orNH;p is 0, 1, 2 or 3;U and V are each independently CH2, C(=O), O or NR6;q and r are each independently 0, 1, 2 or 3, provided that q and r are not both 0;Attorney Docket No.: INMD-209 / 01WO 315953-4493ring E is cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;p is 0, 1, 2 or 3;each R3is independently selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;each R4is independently selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl, heterocyclyl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;each R6is independently selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl.

[0285] A compound of Formula (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, is an embodiment of a compound of Formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

[0286] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1orAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0287] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0288] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0289] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0290] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-C), (II-D), (II-D´), (II-E), (III), (III-1), (III-2), (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-F´), (III-G), (III-H), (III-I), or (III-I´), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2. In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0291] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-C), (II-D), (II-D´), (II-E), (III), (III-1), (III-2), (III-A), (III-B), (III-C), (III-D), (III-E), (III-F), (III-F´), (III-G), (III-H), (III-I), or (III-I´), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R3is halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl or N(C1-6 alkyl)2. In embodiments, R3is halogen, C1-6 alkyl or C1-6 alkylene-OH. In embodiments, R3is F, Cl, CH3, or CH3OH. In embodiments of, R3is F, CH3, or CH3OH.

[0292] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X1is -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O-*, -O-CH2-*, -O-CH2-CH2-*, -CH2-CH2-O-* or -CH2-O-CH2-, wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (la) or (la-A). In embodiments, X1is -CH2CH2-or -CH2CH2CH2-. In embodiments, X1is -CH2CH2-. In embodiments, X1is -CH2CH2CH2-.

[0293] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X2is -CH2- or -CH2CH2-. In embodiments, X2is -CH2-. In embodiments, X2is -CH2CH2-.

[0294] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X1is -CH2CH2- and X2is -CH2CH2-. In embodiments, X1is -CH2CH2CH2- and X2is -CH2-. In embodiments, X1is -CH2CH2- and X2is -CH2-.

[0295] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X3is -NH-, -CH2-NH-*, -CH2-CH2-NH-* or -CH2-NH-CH2-, wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (la) or (la-A). In embodiments, X3is -NH-, or -CH2-NH-*, wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (la) or (la-A). In embodiments, X3is -NH-. In embodiments, X3is -CH2-NH-*, wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (la) or (la- A).

[0296] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,X1is -CH2-CH2-, and X2is -CH2-CH2-;X1is -CH2-CH2-, and X3is -CH2-NH-*;X2is -CH2-CH2-, and X3is -CH2-NH-*; orAttorney Docket No.: INMD-209 / 01WO 315953-4493X1is -CH2-CH2-, X2is -CH2-CH2-, and X3is -CH2-NH-*;wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (la) or (la- A).

[0297] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,X1is -CH2-CH2-CH2-, and X2is -CH2-;X1is -CH2-CH2-CH2-, and X3is -NH-;X2is -CH2-, and X3is -NH-; orX1is -CH2-CH2-CH2-, X2is -CH2-, and X3is -NH-.

[0298] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,X1is -CH2-CH2- and X2is -CH2-;X1is -CH2-CH2- and X3is -CH2-NH-*;X2is -CH2- and X3is -CH2-NH-*; orX1is -CH2-CH2-, X2is -CH2-, and X3is -CH2-NH-*;wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (la) or (la- A).

[0299] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X1is -CH2CH2CH2- and X2is -CH2-.

[0300] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X1is -CH2-CH2- and X2is -CH2-CH2-.

[0301] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X1is -CH2CH2CH2- and X3is -NH-.

[0302] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X1is -CH2-CH2-, and X3is -CH2-NH-*, wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (la) or (la-A).

[0303] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X2is -CH2-and X3is -NH-.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0304] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X2is -CH2-CH2-, and X3is -CH2-NH-*, wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (la) or (la-A).

[0305] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,X1is -CH2-CH2- or -CH2-CH2-CH2-;X2is -CH2- or -CH2-CH2-; and / orX3is -NH- or -CH2-NH-*,wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (la) or (la- A).

[0306] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X1is -CH2CH2- or -CH2CH2CH2-; X2is -CH2- or -CH2CH2-; and X3is -NH- or -CH2NH-*, wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (la) or (la-A). In embodiments, X1is -CH2CH2- or -CH2CH2CH2-; X2is -CH2- or -CH2CH2-; X3is -NH- or -CH2NH-*; and n is 0, wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (la) or (la- A).

[0307] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X1is -CH2CH2-; X2is -CH2CH2-; and X3is -CH2NH-*, wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (I-1), (1-2), (la), (la-A) or (la-B). In embodiments, X1is -CH2CH2-; X2is -CH2CH2-; X3is -CH2NH-*, wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I), (I- 1), (1-2), (la), (la-A) or (la-B); and n is 0.

[0308] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, X1is -CH2CH2CH2-; X2is -CH2-; and X3is -NH-. In embodiments X1is -CH2CH2CH2-; X2is -CH2-; X3is -NH-; and n is 0.

[0309] In embodiments of the compounds of Formula (I), (I- 1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1orAttorney Docket No.: INMD-209 / 01WO 315953-4493embodiments, n is 0 or 1. In embodiments, n is 0. In embodiments, n is 1. In embodiments, R3is halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHC1-6 alkyl, or N(C1-6 alkyl)2. In embodiments, R3is halogen, C1-6 alkyl or C1-6 alkylene-OH. In embodiments, R3is F, Cl, CH3, or CH3OH. In embodiments, R3is F, CH3, or CH3OH.

[0310] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0311] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1orAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0312] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0313] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0314] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or. In embodiments, R1orAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0315] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0316] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0317] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0318] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1orAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0319] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0320] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0321] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0322] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0323] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1orAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0324] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0325] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0326] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0327] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0328] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1orAttorney Docket No.: INMD-209 / 01WO 315953-4493X1(R3)n-T In embodiments, R1or isembodiments, R1or

[0329] In embodiments of the compounds of Formula (I), (lb), (Ib-A), (Ib-B), or (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1or

[0330] In embodiments of the compounds of Formula (I), (lb), (Ib-A), (Ib-B), or (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Y2is -CH2- or -CH2CH2-. In embodiments, Y2is -CH2-. In embodiments, Y2is -CH2CH2-.

[0331] In embodiments of the compounds of Formula (I), (lb), (Ib-A), (Ib-B), or (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R1orAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0332] In embodiments of the compounds of Formula (I), (lb), (Ib-A), (Ib-B), or (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Y4is absent, -CH2- or O. In embodiments, Y4is absent. In embodiments, Y4is -CH2-. In embodiments, Y4is O.

[0333] In embodiments of the compounds of Formula (I), (lb), (Ib-A), (Ib-B), or (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2. In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2.

[0334] In embodiments of the compounds of Formula (I), (lb), (Ib-A), (Ib-B), or (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R3is halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl or N(C1-6 alkyl)2. In embodiments, R3is halogen, C1-6 alkyl or C1-6 alkylene-OH. In embodiments, R3is F, Cl, CH3, or CH3OH. In embodiments of, R3is F, CH3, or CH3OH.

[0335] In embodiments of the compounds of Formula (I), (la), (II), (II- A), (III), (III- 1 ), (III-2), (lb) or (Ic), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Ring A is arylene, heteroarylene, or heterocyclylene.

[0336] In embodiments of the compounds of Formula (I), (la), (II), (II- A), (III), (III- 1 ), (III-2), (lb) or (Ic), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0, 1, 2, 3, or 4. In embodiments, m is 0, 1, or 2. In embodiments, m is 0. In embodiments, m is 1. In embodiments, m is 2.

[0337] In embodiments of the compounds of Formula (I), (la), (II), (II- A), (III), (III- 1 ), (III-2), (lb) or (Ic), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring A is arylene. In embodiments, ring A is monocyclic aryl. In embodiments, ring A isphenylene. In embodiments, ring A is

[0338] In embodiments of the compounds of Formula (I), (la), (II), (II- A), (III), (III- 1 ), (III-2), (lb) or (Ic), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,

[0339] In embodiments of the compounds of Formula (I), (la), (II), (II-A), (III), (III- 1), (III-2), (lb) or (Ic), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring A is heterocyclylene. In embodiments, ring A is 4-15 membered heterocyclylene. In embodiments, ring A is 4-15 membered heterocyclylene comprising 1-3 heteroatoms selectedAttorney Docket No.: INMD-209 / 01WO 315953-4493from O, S or N. In embodiments, ring A is monocyclic heterocyclylene. In embodiments, ring A is polycyclic heterocyclylene.

[0340] In embodiments of the compounds of Formula (I), (1-2), (la), (II), (II- A), (II-E), (III), (III-l), (III-2), (III-E), (lb), (Ib-C), (Ic) or (Ic-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring A is 5- or 6-membered heteroarylene. In embodiments, ring A is 5-membered heteroarylene with 1, 2, or 3 heteroatoms selected from N, O, or S.

[0341] In embodiments of the compounds of Formula (I), (1-2), (la), (II), (II- A), (II-E), (III), (III-l), (III-2), (III-E), (lb), (Ib-C), (Ic) or (Ic-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring A is thiazolylene. In embodiments,. In embodiments,, wherein the asterisk (*) represents the point of attachment to R2.

[0342] In embodiments of the compounds of Formula (I), (1-2), (la), (II), (II- A), (II-E), (III), (III-l), (III-2), (III-E), (lb), (Ib-C), (Ic) or (Ic-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring A is polycyclic arylene, polycyclic heteroarylene or polycyclic heterocyclylene. In embodiments, ring A is bicyclic arylene, bicyclic heteroarylene or bicyclic heterocyclylene.

[0343] In embodiments of the compounds of Formula (I), (1-2), (la), (II), (II- A), (II-E), (III), (III-l), (III-2), (III-E), (lb), (Ib-C), (Ic) or (Ic-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring A is polycyclic heteroarylene. In embodiments, ring A is 8-12 membered polycyclic heteroarylene. In embodiments, ring A is 8-12 membered bicyclic heteroarylene. In embodiments, ring A is 8-10 membered bicyclic heteroarylene. In embodiments, ring A is 8-membered bicyclic heteroarylene. In embodiments, ring A is 9-membered bicyclic heteroarylene. In embodiments, ring A is 10-membered bicyclic heteroarylene.

[0344] In embodiments of the compounds of Formula (I), (1-2), (la), (II), (II- A), (II-E), (III), (III-l), (III-2), (III-E), (lb), (Ib-C), (Ic) or (Ic-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring A is 8-10 membered fused bicyclicAttorney Docket No.: INMD-209 / 01WO 315953-4493heteroarylene comprising 1-3 heteroatoms selected from O, S or N. In embodiments, ring A is 9-membered fused bicyclic heteroarylene comprising 1-3 heteroatoms selected from O, S or N. In embodiments, ring A is 8-membered fused bicyclic heteroarylene comprising 1-3 heteroatoms selected from O, S or N. In embodiments, ring Ais a 5,5-, 5,6-, 6,5-, or 6,6-fused bicyclic heteroarylene comprising 1-3 heteroatoms selected from O, S or N. In embodiments, ring Ais a 5,5,- fused bicyclic heteroarylene comprising 1-3 heteroatoms selected from O, S or N. In embodiments, ring A is 5,6- or 6,5-, fused bicyclic heteroarylene comprising 1-3 heteroatoms selected from O, S or N.

[0345] In embodiments of the compounds of Formula (I), (1-2), (la), (la-B), (II), (II- A), (II-E), (III), (III- 1 ), (III-2), (III-E), (lb), (Ib-C), (Ic), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring Ais a 5,5,- fused bicyclic heteroarylene (R4)mcomprising 1-3 heteroatoms selected from O, S or N. In embodiments,, wherein each X is independently selected from O, S, NH or N(Ci-6 alkyl). Inembodiments, X is O or S. In embodiments,isRing Ais

[0346] In embodiments of the compounds of Formula (I), (1-2), (la), (II), (II- A), (II-E), (III), (III- 1 ), (III-2), (III-E), (lb), (Ib-C), (Ic), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, ring Ais a 5,6- or 6, 5-, fused bicyclic heteroarylene (R4)mcomprising 1-3 heteroatoms selected from O, S or N. In embodiments,, wherein X is selected from O, S, NH or N(C1-6 alkyl). In embodiments, X isAttorney Docket No.: INMD-209 / 01WO 315953-4493(R )m, wherein the asterisk (*) represents the point of attachment to R2.

[0347] In embodiments of the compounds of Formula (I), (1-2), (la), (la-B), (II), (II- A), (II-E), (III), (III- 1 ), (III-2), (III-E), (lb), (Ib-C), (Ic), (Ic-D) or (Ic-E), or a pharmaceutically acceptable (R4)msalt, a stereoisomer, or a deuterated form thereof,, wherein X is selected from O, S, NH or N(C1-6 alkyl), wherein R4is attached to any ring atoms of ring A.In embodiments, X is O or S. In embodiments X is O. In embodiments,r4, wherein R4is attached to any ring atoms of ring A. In embodiments, R4is C1-6 alkyl or halogen. In embodiments, R4is halogen. In embodiments, R4is F, Cl or Br. Inwherein the asterisk (*) represents the point of attachment to R2. In embodiments,Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0348] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (II-C), (ILD), (ILD ), (II-E), (III), (IIL1), (IIL2), (IILA), (III-B), (IILC), (IIL D), (II E), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C) or (LD) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, m is 0, 1 or 2. In embodiments, m is 0. In embodiments, m is 1. In embodiments, m is 2.

[0349] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A), (la-B), (II), (ILA), (ILB), (ILC), (ILD), (ILD ), (ILE), (III), (IIL1), (IIL2), (IILA), (IILB), (IILC), (IIL D), (IILE), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C) or (LD), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R4is C1-6 alkyl, halogen, OH, C1-6 haloalkyl or C3-8 cycloalkyl. In embodiments, R4is C1-6 alkyl, or halogen. In embodiments, R4is halogen. In embodiments, R4is F, Cl or Br. In embodiments, R4is F.

[0350] In embodiments of the compounds of Formula (I), (la), (II), (ILA), (III), (IIL1), (IIL2), (lb) or (Ic), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,represents the point of attachment to R2.

[0351] In embodiments of the compounds of Formula (I), (la), (II), (ILA), (ILD), (ILD ), (II-E), (III), (IIL1), (IIL2), (lb) or (Ic), or a pharmaceutically acceptable salt, a stereoisomer, or aAttorney Docket No.: INMD-209 / 01WO 315953-4493deuterated form thereof,, wherein R4is halogen or Ci-6 alkyl. Inembodiments, R4is F, Cl or Br. In embodiments, R4is F. In embodiments,represents the point of attachment to R2. In embodiments,wherein the asterisk (*) represents the point of attachment toN=N

[0352] In embodiments of the compounds of Formula (1-1), (la-1), (II-B), (II-C) (II-D), (III-A), (III-B), (III-D), (III-D), (Ib-A), (Ib-B), (Ic-A), (Ic-B), or (Ic-C), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof,wherein R4is halogen or Ci-6 alkyl. In embodiments, R4is F, Cl or Br. In embodiments, R4is (R4)mr4F. In embodiments,, wherein the asterisk (*) represents the pointIn embodiments,Attorney Docket No.: INMD-209 / 01WO 315953-4493wherein the asterisk (*) represents the point of attachment toR2. In embodiments,, wherein the asterisk (*) represents the

[0353] In embodiments of the compounds of Formula (I), (la), (II), (II-A), (III), (III- 1 ), (III-2), (lb) or (Ic), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,represents the point of attachment to R2.

[0354] In embodiments of the compounds of Formula (II) or (II-A), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof,wherein the asterisk (*) represents the point of attachment to

[0355] In embodiments of the compounds of Formula (II) or (II-A), or a pharmaceutically (R4)m ( A ) — | acceptable salt, a stereoisomer, or a deuterated form thereof,is

[0356] In embodiments of the compounds of Formula (II) or (II-A), or a pharmaceutically (R4)m Facceptable salt, a stereoisomer, or a deuterated form thereof,wherein the asterisk (*) represents the point of attachment to R2.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0357] In embodiments of the compounds of Formula (II) or (II-A), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof,is wherein the asterisk (*) represents the point of attachment to R2.

[0358] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or apharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,wherein the asterisk (*) represents the point of

[0359] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a (R4)m ( A ) — | pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,is, wherein the asterisk (*) represents the point of attachment to R2.

[0360] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a (R4)m ( A ) — I pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,is F, wherein the asterisk (*) represents the point of attachment to R2.

[0361] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a (R4)m ( A ) — | pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,isN, wherein the asterisk (*) represents the point of attachment to R2.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0362] In embodiments of the compounds of Formula (II), (II-A), (II-B), (II-C), (II-D), (III-B), (III-C), (III-D), (lb), (Ib-A), (Ib-B), (Ic-A), (Ic-B) or (Ic-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, p is 0, 1, 2 or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3.

[0363] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-E), (III), (III-l), (III-2), (III-A), (III-E), (III-G), (lb), (Ib-A), (Ib-C), (Ic), (Ic-A), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(Ci-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl, heterocyclyl heteroaryl,or 1, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl; wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl. In embodiments, L is CH2 O, NH, or S(=O)2. In embodiments, L is CH2 or S(=O)2. In embodiments, ring E is heterocyclyl. In embodiments, ring E is N-heterocyclyl. In embodiments, R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C3-6 cycloalkyl, CN, Ci-6 alkylene-heterocyclyl or S(=O)2-heterocyclyl. In embodiments, R5is selected from halogen, oxo, C1-6 alkyl, CN, CH2-heterocyclyl or S(=O)2-heterocyclyl. In embodiments, R5is selected from halogen, oxo, C1-6 alkyl or CN. In embodiments, R5is selected from F, oxo, CH3, CN,N N0=^=0NJor„~1~~ inembodiments, R5is selected from F, CH3, CN,N0=^=0orinembodiments, R5is selected from F, CH3 or CN.

[0364] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-A), (II-B), (II-E), (III), (III-l), (III-2), (III-A), (III-E), (III-G), (lb), (Ib-A), (Ib-C), (Ic), (Ic-A), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5is halogen. In embodiments, R5is F.

[0365] In embodiments of the compounds of Formula (II-C), (II-D), (III-B), (III-C), (III-D), (III-F), (III-H), (III-I), (III-E), (Ib-B), (Ic-B), or (Ic-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5is selected from halogen, oxo, C1-6 alkyl, OCi-Attorney Docket No.: INMD-209 / 01WO 315953-44936 alkyl, C3-6 cycloalkyl, CN, C1-6 alkylene-heterocyclyl or S(=O)2-heterocyclyl. In embodiments, R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl or CN. In embodiments, R5is selected from halogen, oxo, C1-6 alkyl or CN. In embodiments, R5is selected from F, CH3 or CN. In embodiments, R5is selected from F, CH3 or CN.

[0366] In embodiments of the compounds of Formula (II-C), (II-D), (III-B), (III-C), (III-D), (III-F), (III-H), (III-I), (III-F), (Ib-B), (Ic-B), or (Ic-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R5is halogen. In embodiments, R5is F.

[0367] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (II-B), (ILE), (III), (IIL1), (III-2), (III-A), (III-E), (lb), (Ib-A), (Ic), (Ic-A), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-C1-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl; wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-NH2, Ci-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(C1-6 alkylene-O-C1-6 alkyl)(C1-6 alkyl) or heterocyclyl. In embodiments, R6is C1-6 alkyl, C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(C1-6 alkylene-O-C1-6 alkyl)(Ci-6 alkyl). In embodiments, R6is H, CH3,In embodiments, R6is CH3,. In embodiments, R6is CH3. In embodiments, R6is. In embodiments, R6is CH3,. In embodiments, R6is H.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0368] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (II-B), (ILE), (III), (IIL1), (III-2), (IILA), (III-E), (IILG), (lb), (Ib-A), (Ic), (Ic-A), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6is selected from H, Ci-6 alkyl, deuterated Ci-6 alkyl, Ci-6 alkylene-NEE, Ci-6 alkylene-NH(Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), Ci-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl; wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl. In embodiments, R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6alkyl)(Ci-6 alkyl). In embodiments, R6is H, CH3, CD3,. In embodiments, R6is CH3, CD3,. In embodiments, R6is CH3 or CD3. In embodiments,R6is CH3. In embodiments, R6isembodiments, R6is CH3, CD3,. In embodiments, R6is H.

[0369] In embodiments of the compounds of Formula (ILC), (ILD), (III-B), (IILC), (IILD), (Ib-B), (Ic-B) or (Ic-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, In embodiments, R6is C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6is C1-6 alkyl. In embodiments, R6is C1-3 alkyl. In embodiments, R6Attorney Docket No.: INMD-209 / 01WO 315953-4493In embodiments, R6is CH3.In embodiments, R6is

[0370] In embodiments of the compounds of Formula (II), (II- A), (II-B), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl. In embodiments, R6ais C2-6 alkyl. InNembodiments, R6ais CH2CH3,embodiments, R6ais CH2CH3.

[0371] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II-E), (III), (III- 1 ), (III-2), (III- A), (III-E), (lb), (Ib-A) or (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is 6-12 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is monocyclic or bicyclic 6-10 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is monocyclic or bicyclic 6-10 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is monocyclic 6-10 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is phenyl optionally substituted with 1-5 groups independently selected from R5orR6. In embodiments, R2is phenyl(R5)PHOoptionally substituted with 1-5 R5. In embodiments,R2is, wherein L is CH2, O, S(=O)2 or NH, ring E is cycloalkyl, aryl, heteroaryl or heterocyclyl optionally substituted with 1-3 group selected from selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl, and p is 0, 1, 2, 3, or 4.

[0372] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II-E), (III), (III- 1 ), (III-2), (III- A), (III-E), (lb), (Ib-A) or (Ib-C), or a pharmaceutically acceptableAttorney Docket No.: INMD-209 / 01WO 315953-4493salt, a stereoisomer, or a deuterated form thereof, R2is 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is 5-10 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is monocyclic, bicyclic, or tricyclic 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is monocyclic, bicyclic, or tricyclic 5-10 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is monocyclic, bicyclic, or tricyclic 5-9 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6.

[0373] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II-E), (III), (III- 1 ), (III-2), (III- A), (III-E), (lb), (Ib-A) or (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a 5-20 membered heteroaryl containing 1-4 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is a monocyclic, bicyclic, tricyclic, or tetracyclic 5-20 membered heteroaryl containing 1-4 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is a monocyclic, bicyclic, tricyclic, or tetracyclic 9-14 membered heteroaryl containing 1-4 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is a bicyclic 8-10 membered heteroaryl containing 1-4 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is a bicyclic 9-10 membered heteroaryl containing 1-4 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is a bicyclic 9-membered heteroaryl containing 1-4 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6.

[0374] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II-E), (III), (III-l), (III-2), (III- A), (III-E), (lb), (Ib-A) or (Ib-C), a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is a fused bicyclic 8-10 membered heteroaryl containing 1-4 heteroatoms selected from N, S or O, wherein the heteroaryl isAttorney Docket No.: INMD-209 / 01WO 315953-4493optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is a fused bicyclic 9-10 membered heteroaryl containing 1-4 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is a fused bicyclic 9-membered heteroaryl containing 1-4 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is a fused bicyclic 10-membered heteroaryl containing 1-4 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6. In embodiments, R2is a 5,5-, 5,6-, 6,5-, or 6,6-fused bicyclic heteroaryl, optionally substituted with 1, 2, 3, or 4 groups selected from R5or R6. In embodiments, R2is a 5,5-, 5,6-, 6,5-, or 6,6-fused bicyclic heteroaryl, comprising one aromatic ring, wherein R2is optionally substituted with 1, 2, 3, or 4 groups selected from R5or R6. In embodiments, R2is a 5,5-, 5,6-, 6,5-, or 6,6-fused bicyclic heteroaryl, comprising two aromatic rings, wherein R2is optionally substituted with 1, 2, 3, or 4 groups selected from R5or R6.

[0375] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II- E), (III), (III- 1 ), (III-2), (III- A), (III-E), (lb), (Ib-A) or (Ib-C), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, R2iswhereinring B and ring C are each independently an aromatic ring optionally substituted with 1-3 group selected from R5or R6;ring D is a cycloalkyl, cycloalkenyl, heterocyclyl or heterocycloalkenyl optionally substituted with 1-3 group selected from R5or R6;L is CH2, O, NH or S(=O)2;ring E is cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, Ci-6 alkyl, OCi-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;U and V are each independently CH2, C(=O), O or NR6;Attorney Docket No.: INMD-209 / 01WO 315953-4493W is N or CH;p is 0, 1, 2 or 3;q and r are each independently 0, 1, 2 or 3, provided that q and r are not both 0;R5is selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl or heterocyclyl heteroaryl; wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; and R6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl; wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

[0376] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II-E), (III), (III-l), (III-2), (III- A), (III-E), (III-G), (lb), (Ib-A) or (Ib-C), or a pharmaceutically U-V(R5)P-^ T acceptable salt, a stereoisomer, or a deuterated form thereof, R2iswhereinring B and ring C are each independently an aromatic ring optionally substituted with 1-3 group selected from R5or R6;ring D is a cycloalkyl, cycloalkenyl, heterocyclyl or heterocycloalkenyl optionally substituted with 1-3 group selected from R5or R6;L is CH2, O, NH or S(=O)2;Attorney Docket No.: INMD-209 / 01WO 315953-4493ring E is cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;U and V are each independently CH2, C(=O), O or NR6;W is N or CH;p is 0, 1, 2 or 3;q and r are each independently 0, 1, 2 or 3, provided that q and r are not both 0;R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl or heterocyclyl heteroaryl; wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; and R6is selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl; wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

[0377] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II- A), (II-B), (II-E), (III), (III- 1), (III-2), (III- A), or (III-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof:Attorney Docket No.: INMD-209 / 01WO 315953-4493ring B and ring C are each independently an aromatic ring optionally substituted with 1-3 group selected from R5or R6;Q is CH, CR5orN;wherein X is CH2 or NR6;W is N or CH;L is CH2, O, S(=O)2or NH;ring E is cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;p is 0, 1, 2 or 3;U and V are each independently CH2, C(=O), O or NR6;q and r are each independently 0, 1, 2 or 3, provided that q and r are not both 0;R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl heteroaryl; wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;R6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl; wherein the C1-6 alkyl, NH2, N(CI-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(CI-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl.

[0378] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II),Attorney Docket No.: INMD-209 / 01WO 315953-4493(ILA), (II-B), (ILE), (III), (III-l), (ID-2), (III- A), (III-E), or (IILG), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof:ring B and ring C are each independently an aromatic ring optionally substituted with 1-3 group selected from R5or R6;Q is CH, CR5orN;wherein X is CH2 or NR6;W is N or CH;L is CH2, O, S(=O)2or NH;ring E is cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;p is 0, 1, 2 or 3;U and V are each independently CH2, C(=O), O or NR6;q and r are each independently 0, 1, 2 or 3, provided that q and r are not both 0;R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl,Attorney Docket No.: INMD-209 / 01WO 315953-4493CONHCI-6 alkyl, C0N(C1-6 alkyl)2, NHCOCI-6 alkyl, SCi-6 alkyl, S(=0)2 alkyl, heterocyclyl heteroaryl; wherein the alkyl, OCi-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;R6is selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl; wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl.

[0379] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (II-B), (ILE), (III), (III-l), (III-2), (III- A), (IILE), or (IILG), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof:Attorney Docket No.: INMD-209 / 01WO 315953-4493(R5)P- 'R6, wherein,ring B and ring C are each independently an aromatic ring optionally substituted with 1-3 group selected from R5or R6;Q is CH, CR5aor N;wherein X is CH2 or NR6;W is N or CH;L is CH2, O, S(=O)2or NH;ring E is cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;p is 0, 1, 2 or 3;U and V are each independently CH2, C(=O), O or NR6;q and r are each independently 0, 1, 2 or 3, provided that q and r are not both 0;R5and R5aare each independently halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl, heterocyclyl heteroaryl; wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl;R6is selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl; wherein the C1-6 alkyl, NH2, N(CI-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(CI-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0380] In one embodiment of a compound of Formula (I), (1-1), (1-2), (la), (la- A), (la-B), (II), (ILA), (II-B), (ILE), (III), (III-l), (in-2), (III- A), (IILE), or (IILG), or a pharmaceutically Q=N(R5)P~^ T acceptable salt, a stereoisomer, or a deuterated form thereof, R2is, Q is CH, CF, or N. In a further embodiment, Q is CH. In another embodiment, Q is CF. In still another embodiment, Q is N.

[0381] In embodiments of compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II- A), (ILB), (ILE), (III), (IIL1), (IIL2), (IILA), (IILE), or a pharmaceutically acceptable salt, a0, 1, 2 or 3. In embodiments, p is 0 or 1. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl or CN. In embodiments, R5is selected from halogen, oxo, Ci-6 alkyl or CN. In embodiments, R5is selected from F, oxo, CH3 or CN. In embodiments, R5is selected from F, CH3 or CN. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) orAttorney Docket No.: INMD-209 / 01WO 315953-4493heterocyclyl. In embodiments, R6is Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl) or Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6isembodiments, R6is CH3,embodiments, R6is CH3. In embodiments, R6isIn embodiments, R6is CH3,. In embodiments, R6is H. In embodiments, R6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene- NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-C1-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl. In embodiments, R6ais C2-6 alkyl. InNembodiments, R6ais CH2CH3,embodiments, R6ais CH2CH3.

[0382] In embodiments of compounds of Formula (I), (1-1), (1-2), (la), (la- A), (la-B), (II), (II- A), (II-B), (II-E), (III), (III-l), (III-2), (III-A), (III-E), or (III-G), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493embodiments, p is 0 or 1. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl or CN. In embodiments, R5is selected from halogen, oxo, Ci-6 alkyl or CN. In embodiments, R5is selected from F, oxo, CH3 or CN. In embodiments, R5is selected from F, CH3 or CN. In embodiments, R5is F. In embodiments, p is 1 and R5is F. In embodiments, R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6is H, CH3, CD3,R6is CH3, CD3, or. In embodiments, R6isCH3 or CD3. In embodiments, R6is CH3. In embodiments, R6is\ / . In embodiments, R6is H. In embodiments, R6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl.Attorney Docket No.: INMD-209 / 01WO 315953-4493In embodiments, R6ais C2-6 alkyl. In embodiments, R6ais CH2CH3, II or. In embodiments, R6ais CH2CH3.

[0383] In embodiments of compounds of Formula (I), (1-1), (1-2), (la), (la- A), (la-B), (II), (II-A), (II-B), (II-E), (III), (III-l), (III-2), (in-A), (III-E), (lb), (Ib-A), or (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2isembodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl or CN. In embodiments, R5is selected from halogen, oxo, C1-6 alkyl or CN. In embodiments, R5is selected from F, oxo, CH2or CN. In embodiments, R5is selected from F, CH2or CN. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(Ci-6Attorney Docket No.: INMD-209 / 01WO 315953-4493N alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6is H, CH3,In embodiments, R6is CH3,In embodiments, R6is CH3. Inembodiments, R6is or. In embodiments, R6is CH3,. In embodiments, R6is H. In embodiments, R6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl. In embodiments, R6ais C2-6 alkyl. In embodiments, R6ais CH2CH3,In embodiments, R6ais CH2CH3.

[0384] In embodiments of compounds of Formula (I), (1-1), (1-2), (la), (la- A), (la-B), (II), (II-A), (II-B), (II-E), (III), (III-l), (III-2), (in-A), (in-E), (lb), (Ib-A), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuteratedembodiments, p is 0, 1, 2 or 3. In embodiments, p is 0 or 1. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C3-6 cycloalkyl, CN, C1-6 alkylene-heterocyclyl or S(=O)2-heterocyclyl. In embodiments, R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl or CN. In embodiments, R5is selected from halogen, oxo, C1-6 alkyl or CN. In embodiments, R5isAttorney Docket No.: INMD-209 / 01WO 315953-4493selected from F, oxo, CH3 or CN. In embodiments, R5is selected from F, CH3 or CN. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(Ci-6alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6is H, CH2,N. In embodiments, R6is CH2,In embodiments, R6is CH2. Inembodiments, R6is. In embodiments, R6is CH3,. In embodiments, R6is H. In embodiments, R6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl. In embodiments, R6ais C2-6 alkyl. In embodiments, R6ais CH2CH3,. In embodiments, R6ais CH2CH3.

[0385] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-E), (III), (III-l), (III-2), (III- A), (III-E), (lb), (Ib-B) or (Ib-C), or a pharmaceuticallyacceptable salt,R2is, wherein U and V are each independently CH2, C(=O), O or NR6. In embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R5is selected from halogen,U-V L XR6CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments,R2is embodiments, U and V are each independently CH2, C(=O) or O. In embodiments, U is O orAttorney Docket No.: INMD-209 / 01WO 315953-4493CH2. In embodiments, V is C(=O). In embodiments, U is O, and V is C(=O). In embodiments,U is CH2, and V is C(=O). In embodiments,R2is

[0386] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (ILE), (III), (IIL1), (III-2), (IILA), (IILE), (lb), (Ib-B) or (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2isO-A™. in embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected fromhalogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R2is embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), or Ci-6 alkylene-N(Ci- 6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6is Ci-6 alkyl. In embodiments, R6is. In embodiments, R6is CH3. Inembodiments, R6is

[0387] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (ILE), (III), (IIL1), (IIL2), (IILA), (IILE), (IILG), (lb), (Ib-B) or (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is. In embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0. In embodiments,Attorney Docket No.: INMD-209 / 01WO 315953-4493p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from O0-4 rj halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl. In embodiments,R2is. In embodiments, R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6N is C1-6 alkyl or deuterated C1-6 alkyl. In embodiments, R6is CH3, CD3,N. In embodiments, R6is CH3 or CD3. In embodiments,R6is CH3. In embodiments, R6is

[0388] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (ILE), (III), (IIL1), (III-2), (III-A), (IILE), (lb), (Ib-B) or (Ib-C), or apharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0389] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (ILE), (III), (IIL1), (111-2), (III- A), (IILE), (IILG), (lb), (Ib-B) or (Ib-C), or apharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,R2is

[0390] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (ILE), (III), (III-l), (IIL2), (IILA), (IILE), (lb), (Ib-B) (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a O OQ-4 N_p6a N_R6a(R5)PHJQF of deuterated form thereof,R2is. In embodiments, R2is ~™*"~. In embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl. In embodiments, R6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 memberedAttorney Docket No.: INMD-209 / 01WO 315953-4493heterocyclyl, Ci-6 alkylene-NH2, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-NH(Ci-6 alkyl), Ci- 6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl. In embodiments, R6ais C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6N alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6ais

[0391] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (II-B), (ILE), (III), (III-l), (111-2), (IILA) (III-E), (lb), (Ib-A) or (Ib-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is O O / N~_R6a / N__p6a. In embodiments, R2is. In embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-NH(Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or Ci-6 alkylene-heterocyclyl. In embodiments, R6ais C2-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6ais CH2CH3, I I orAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0392] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (II-E), (III), (IIL1), (IIL2), (III-A), (IILE), (lb), (Ib-B), (Ib-C), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2isK. In embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl. In embodiments, R2isR. In embodiments, R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6is C1-6 alkyl or deuterated C1-6 alkyl. In embodiments, R6is C1-6 alkyl. In embodiments, R6is CH3 or CD3. In embodiments, R6is CH3. In embodiments, R2is

[0393] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (ILE), (III), (IIL1), (IIL2), (III-A), (IILE), (lb), (Ib-B), (Ib-C), (Ic-D) or (Ic-E),Bor a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is. In embodiments, ring B and ring C are each independently a 5-6 membered aromatic ring optionally substituted with 1-3 group selected from R5or R6. In embodiments, ring B is a 5-membered aromatic ring optionally substituted with 1-3 group selected from R5or R6, and ring C is a 6-membered aromatic ring optionally substituted with 1-3 group selected from R5or R6. In embodiments, ring B is a 6-membered aromatic ring optionally substituted with 1-3 group selected from R5or R6, and ring C is a 5-membered aromatic ring optionally substituted with 1-3 group selected from R5or R6. In embodiments, the aromatic ring is an aryl or heteroarylAttorney Docket No.: INMD-209 / 01WO 315953-4493ring. In embodiments, Ring B isconnected to ring C through any atoms on ring B. In embodiments, Ring B is, wherein the asterisk (*) represents the point of attachment to ring N R6" N-RC. n m oQ — ~ / D\ 5 5 I e b diments, ring C isv, wherein Q is CH, CR or N. In embodiments, R is Ci-6 alkyl, OCi-6 alkyl or halo. In embodiments, Q is CH or N. In embodiments, Ring C is N R6 N D6 M 'N-KN'' 'N-R(R )p, (R)p, ' (R)por—, wherein ring C is connected to ring Bthrough any atoms on ring C. In embodiments, Ring C isor, wherein the asterisk (*) represents the point of attachment to ring B.

[0394] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (II-E), (III), (IIL1), (III-2), (III-A), (IILE), (lb), (Ib-B), (Ib-C), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2iswherein Q is CH, CR5or N. InAttorney Docket No.: INMD-209 / 01WO 315953-4493or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl. In embodiments, R5is halogen or C1-6 alkyl. In embodiments, R5is F or CH3. In embodiments, p is 2 and R5is CH3. In embodiments, p is 1 and R5is CH3. In embodiments, R6is C1-6 alkyl or heterocyclyl. In embodiments, R6is C1-6 alkyl or 4-6 membered heterocyclyl.I NIn embodiments, R6is CH3 or ~~k~. In embodiments, R6is CH3 or. In embodiments,IR6ais C2-6 alkyl or heterocyclyl. In embodiments, R6ais y. In embodiments, R6is y.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0395] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (II-E), (III), (IIL1), (III-2), (III-A), (IILE), (lb), (Ib-B), (Ib-C), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2isor 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5or R5ais selected from halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R5or R5ais halogen or C1-6 alkyl. In embodiments, R5or R5ais F or CH3. In embodiments, R5ais F. In embodiments, p is 2 and R5is CH3. In embodiments, p is 1 and R5is CH3. In embodiments, R6is C1-6 alkyl or heterocyclyl. In embodiments, R6is C1-6Nalkyl or 4-6 membered heterocyclyl. In embodiments, R6is CH3or In embodiments, R6In embodiments, R6ais C2-6 alkyl or heterocyclyl. In embodiments, R6aisAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0396] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (ILE), (III), (IIL1), (III-2), (IILA), (IILE), (IILG), (lb), (Ib-B), (Ib-C), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R5is halogen or C1-6 alkyl. In embodiments, R5is F or CH2. In embodiments, p is 2 and R5is CH3. In embodiments, p is 1 and R5is CH3. In embodiments, p is 1 and R5is F. In embodiments, R6is C1-6 alkyl or heterocyclyl. In embodiments, R6is C1-6 alkyl or 4-6Attorney Docket No.: INMD-209 / 01WO 315953-4493 membered heterocyclyl. In embodiments, R6is CH3 or. In embodiments, R6is CH3 or

[0397] In embodiments of the compounds of Formula (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic- E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2InAttorney Docket No.: INMD-209 / 01WO 315953-4493embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl. In embodiments, R5is halogen or C1-6 alkyl. In embodiments, R5is F or CH3. In embodiments, p is 2 and R5is CH3. In embodiments, p is 1 and R5is CH3. In embodiments, R6is C1-6 alkyl or heterocyclyl. In embodiments, R6is C1-6 alkyl or 4-6membered heterocyclyl. In embodiments, R6is CH3 or o ~~L. In embodiments, R6is CH3 or

[0398] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (II-B), (ILE), (III), (III-l), (III-2), (III-A), (III-E), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2£ D )WxA:::^Z(R5)P^t / is-™ I1™-. In embodiments, ring D is cycloalkyl, heterocyclyl, cycloalkenyl or heterocycloalkenyl ring. In embodiments, ring D is 5-6 membered cycloalkyl, 5-6 membered heterocyclyl, 5-6 membered cycloalkenyl or 5-6 membered heterocycloalkenyl ring. In embodiments, ring D is 5-6 membered cycloalkenyl or heterocycloalkenyl ring. In embodiments, W is N. In embodiments W is CH. In embodiments, ring D is a 6-membered R6_| / \cycloalkenyl or heterocycloalkenyl ring. In embodiments, ring D isorAttorney Docket No.: INMD-209 / 01WO 315953-4493V(R5)P. In embodiments, R2is, wherein W is N or CH, and X is CH2or NR6. In embodiments, W is N and X is CH2. In embodiments, W is CH and X is NR6. In embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R5is C1-6 alkyl. In embodiments, R5is CH3. In embodiments, R6is H or C1-6 alkyl. In embodiments, R6is H.

[0399] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (II-E), (III), (III-l), (IIL2), (IILA), (IILE), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic), (Ic-A), (Ic-B), (Ic-C), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a NNdeuterated form thereof, R2In embodiments,R2is embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R5is C1-6 alkyl. In embodiments, R5is CH3.HNIn embodiments, R6is H or C1-6 alkyl. In embodiments, R6is H. In embodiments,R2is

[0400] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILA), (ILB), (ILE), (III), (ULI), (IIL2), (IILA), (IILE), (lb), (Ib-A), (Ib-B), (Ib-C), (Ic-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493. In embodiments, p is 0, 1, 2, 3, or 4. In embodiments, L is CH2, O, S(=O)2orNH. In embodiments, L is CH2or S(=O)2. In embodiments,R2is. In embodiments, ring E is heterocyclyl optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl. In embodiments, ring E is 3-7 membered heterocyclyl optionally optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl. In embodiments, ring E is 4-6 membered heterocyclyl optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl. In embodiments, ring E is 4-6 membered N-heterocyclyl optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, C1-6 alkyl, OC1-6 alkyl, COOH, cycloalkyl, aryl,heterocyclyl or heteroaryl. In embodiments, ring E isorH. In embodiments,ring Eis or —I—. In embodiments, R6is C1-6 alkyl. In embodiments, R6is CH3. In Nembodiments, R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, CN, Ci-6 alkyl, OCi-6 alkyl, or C3-6 cycloalkyl. In

[0401] In embodiments of the compounds of Formula (Ic), (Ic-A), (Ic-D) or (Ic-E), or apharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,In embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, CN,0=^=0C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments,R2is

[0402] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-E), (III), (III-l), (III-2), (III- A), (III-E), (lb), (Ib-A) or (Ib-C), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof,R2is embodiments, U and V are each independently CH2, C(=O), O or NR6. In embodiments, U and V are each independently CH2, C(=O), O orNCH2. In embodiments, U is CH2, C(=O) or NCH3, and V is C(=O) or O. In embodiments, U is NCH3 and V is C(=O). In embodiments, U is C(=O) and V is O. In embodiments, U is CH2 and V is O. In embodiments, q and r are each independently 1, 2 or 3. In embodiments, q is 1, 2 or 3, and r is 1 or 2. In embodiments, q is 1 and r is 1. In embodiments, q is 2, and r is 2. In embodiments, q is 3 and r is 1. In embodiments, p 0 or 1. In embodiments, p is 0. In embodiments, R6is C1-6 alkyl or heterocyclyl. InAttorney Docket No.: INMD-209 / 01WO 315953-4493embodiments, R6is Ci-6 alkyl or 3-6 membered-heterocyclyl. In embodiments, R6is CH3 oroxetanyl. In embodiments, R6is CH3 or

[0403] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (n-B), (II-E), (III), (III- 1), (III-2), (III- A), (III-E), (lb), (Ib-A) or (Ib-C), or a pharmaceuticallyembodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R5is C1-6 alkyl or halo. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is C1-6 alkyl or heterocyclyl. In embodiments, R6is C1-6 alkyl or 3-6 membered-heterocyclyl. In embodiments, R6is CH3 or oxetanyl. In embodiments, R6is

[0404] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (n-B), (II-E), (III), (III- 1), (III-2), (III- A), (III-E), (lb), (Ib-A) or (Ib-C), or a pharmaceuticallyAttorney Docket No.: INMD-209 / 01WO 315953-44930, 1, 2 or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R5is C1-6 alkyl or halo. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-C1-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is C1-6 alkyl or heterocyclyl. In embodiments, R6is C1-6 alkyl or 3-6 membered-heterocyclyl. In embodiments, R6is CH3 oroxetanyl. In embodiments, R6is CH3 or. In embodiments, R6is CH3. In embodiments,R2is

[0405] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A), (la-B), (II), (ILB), (II-E), (III), (III-l), (III-2), (III-A), (III-E), (lb), (Ib-A), (Ib-C), (Ic-D) or (Ic-E), or apharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0406] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (n-B), (n-E), (III), (III-l), (III-2), (III-A), (in-E), (lb), (Ib-A), (Ib-C), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0407] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILB), (II-E), (III), (III-l), (III-2), (III-A), (III-E), (III-G), (lb), (Ib-A), (Ib-C), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0408] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (ILB), (II-E), (III), (III-l), (III-2), (III-A), (in-E), (lb), (Ib-A), (Ib-C), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is

[0409] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la-A), (la-B), (II), (II-B), (II-E), (III), (III-l), (III-2), (III-A), (III-E), (lb), (Ib-A), (Ib-C), (Ic), (Ic-A), (Ic-D) or (Ic-E), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0410] In embodiments of the compounds of Formula (II) or (II-A), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, R2is or N=N

[0411] In embodiments of the compounds of Formula (II) or (II-A), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof,R2is

[0412] In embodiments of the compounds of Formula (II) or (II-A), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof,R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0413] In embodiments of the compounds of Formula (II) or (II-A), or a pharmaceutically N=Nacceptable salt, a stereoisomer, or a deuterated form thereof,R2is

[0414] In embodiments of the compounds of Formula (III), (III- 1 ), (III-2), (III-A), (III-E), (III- G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is O

[0415] In one embodiment of the compounds of Formula (III), (III-l), (III-2), (III-A), (III-E), (III-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2O

[0416] In embodiments of the compounds of Formula (III), (III- 1 ), (III-2), (III-A), (III-E), (III-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is N=N

[0417] In embodiments of the compounds of Formula (III), (III- 1 ), (III-2), (III-A), (III-E), (III-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2is

[0418] In one embodiment of a compounds of Formula (III), (III-l), (III-2), (III-A), (III-E), (III-G), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, R2Attorney Docket No.: INMD-209 / 01WO 315953-4493is

[0419] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,In embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0 or 1. In embodiments, p is 0. In embodiments, p is 1. In embodiments, R5is selected from halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), or Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6NNis Ci-6 alkyl. In embodiments, R6is CH3, orAttorney Docket No.: INMD-209 / 01WO 315953-4493N N-^ / ° In embodiments, R6is CH3. In embodiments, R6is, or

[0420] In embodiments of the compounds of Formula (I), (1-1), (1-2), (la), (la- A) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,embodiments, p is 0 or 1. In embodiments, p is 0. In embodiments, p is 1. In embodiments, R5is selected from halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6is C1-6 alkyl. In embodiments, R6is CH3, I,

[0421] In embodiments of the compounds of Formula (I), (1-1), (la) or (la-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,Attorney Docket No.: INMD-209 / 01WO 315953-4493N. In embodiments, Q is CH. In embodiments, Q is N. In embodiments, p is 0 or 1. In embodiments, p is 0. In embodiments, p is 1. In embodiments, R5is selected from halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), or Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). Inembodiments, R6is Ci-6 alkyl. In embodiments, R6is CH3,In embodiments, R6is CH3. In embodiments, R6Attorney Docket No.: INMD-209 / 01WO 315953-4493a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,

[0423] In embodiments of the compounds of Formula (I) or (la) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,Attorney Docket No.: INMD-209 / 01WO 315953-4493embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0 or 1. In embodiments, p is 0. In embodiments, p is 1. In embodiments, R5is selected from halogen, CN, C1-6 alkyl, OC1-6 alkyl, or C3-6 cycloalkyl. In embodiments, R6is H, C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or heterocyclyl. In embodiments, R6is Ci-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-(N-heterocyclyl), or Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6NNis Ci-6 alkyl. In embodiments, R6is CH3, orIn embodiments, R6is CH3. In embodiments, R6isIn embodiments, p is 0, and R6is CH3. In embodiments,wherein the asterisk (*) represents the point of N-Nattachment toR2, and R2is

[0424] In embodiments of the compounds of Formula (I), (I-a), (1-2), (la) or (la-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0425] In embodiments of the compounds of Formula (I), (la) or (la- A), or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof,wherein the asterisk (*) represents the point of attachment toR2, and R2is

[0426] In embodiments of the compounds of Formula (I), (1-1), (la), (la- A), (II), (II- A), (II-E), (III), (III- 1), (III-2), (III-A), (lb), (Ib-A), (Ic) or (Ic-A) or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof,In embodiments,Attorney Docket No.: INMD-209 / 01WO 315953-4493In embodiments, Q is CH or N. In embodiments, Q is CH. In embodiments, Q is N. In embodiments, m is 0, 1 or 2. In embodiments m is 0. In embodiments, m is 1. In embodiments, R4is halogen, OH, C1-6 haloalkyl or C3-8 cycloalkyl. In embodiments, R4is C1-6 alkyl or halogen. In embodiments, R4is halogen. In embodiments, R4is F, Cl or Br. In embodiments, R4is F. In embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, Ci- 6 alkyl, OCi-6 alkyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl or N(C1-6 alkyl)2. In embodiments, R5is selected from halogen, C1-6 alkyl, OC1-6 alkyl, C3-6 cycloalkyl, CN or OH. In embodiments, R6is C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). In embodiments, R6is C1-6 alkyl. Inembodiments, R6is CH3,embodiments, R6is CH3. In embodiments, R6is or N O. In embodiments, m is 0, p is 0 and R6is CH3. In embodiments, m is 0, p is 0, Q is CH, and R6is CH3. In embodiments, m is 0, p is 0, Q is N, and R6is CH3.

[0427] In embodiments of the compounds of Formula (I), (la), (II), (II- A), (III), (III- 1 ), (III-2), or (lb) or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0428] In embodiments of the compounds of Formula (1-1), (la- A), (II-B), (III- A) or (Ib-A), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof,Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0429] In embodiments of the compounds of Formula (Ic), or a pharmaceutically acceptable

[0430] In embodiments of the compounds of Formula (Ic-A), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof,Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0431] In embodiments of the compounds of Formula (I) or (la), or a pharmaceuticallyor Ci-3 alkyl. In embodiments, X1is -CH2-CH2-, and X2is -CH2-CH2-; X1is -CH2-CH2-, and X3is -CH2-NH-*; and / or X2is -CH2-CH2-, and X3is -CH2-NH-*, wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I). In embodiments, m is 0. In embodiments, m is 1. In embodiments, m is 1 and R4is F. In embodiments, R6is CH3.

[0432] In embodiments of the compounds of Formula (I) or (la), or a pharmaceutically (R4)macceptable salt, a stereoisomer, or a deuterated form thereof, R1isAttorney Docket No.: INMD-209 / 01WO 315953-4493R4is halogen; R6is H or C1-3 alkyl; and R6ais C2-6 alkyl. In embodiments, m is 0. In embodiments, m is 1. In embodiments, m is 1 and R4is F. In embodiments, R6is CH3. In embodiments, R6ais CH2CH3.

[0433] In embodiments of the compounds of Formula (I) or (la), or a pharmaceuticallyhalogen; and R6is H or C1-3 alkyl. In embodiments, m is 0. In embodiments, m is 1. In embodiments, m is 1 and R4is F. In embodiments, R6is CH3. In embodiments, R1isAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0434] In embodiments of the compounds of Formula (I) or (la), or a pharmaceuticallyorN, wherein the asterisk (*) represents the point of attachment to R2. In

[0435] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptablehalogen; and R6is H or C1-3 alkyl. In embodiments, m is 0. In embodiments, m is 1. In embodiments, m is 1 and R4is F. In embodiments, R6is CH3.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0436] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, nis 0; R2is

[0437] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptable O|— ( A ) — | salt, a stereoisomer, or a deuterated form thereof, nis 0; R2is; and is

[0438] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, nis 0; R2is, wherein the asterisk (*) represents the point of attachment to R2.

[0439] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, nis 0; R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493N, wherein the asterisk (*) represents the point of attachment to R2.

[0440] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, nis 0; R2is; and ' is

[0441] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptable r-N Y fY 4(R> [— f A ) — | salt, a stereoisomer, or a deuterated form thereof, nis 0; R2is; and is F, wherein the asterisk (*) represents the point of attachment to R2.

[0442] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptable r-N C 4(R> I— ( A ) — | salt, a stereoisomer, or a deuterated form thereof, nis 0; R2is -0™. •; and isYHN, wherein the asterisk (*) represents the point of attachment to R2.

[0443] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptable N=NO'" salt, a stereoisomer, or a deuterated form thereof, nis 0; R2is ~0-~; and isAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0444] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptable N=Nsalt, a stereoisomer, or a deuterated form thereof, nis 0; R2is O'"; and KO '; is F, wherein the asterisk (*) represents the point of attachment to R2.

[0445] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptable N=Nsalt, a stereoisomer, or a deuterated form thereof, n is 0; R2is O"; and KO is 'SyN-v, wherein the asterisk (*) represents the point of attachment to R2.

[0446] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, n is 0; R2isF; and (R4)m

[0447] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, n is 0; R2iswherein the asterisk (*) represents the point of attachment to R2.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0448] In embodiments of the compounds of Formula (II), or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, n is 0; R2iswherein the asterisk (*) represents the point of attachment to R2.

[0449] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a; R4is halogen; and R6is H or C1-3 alkyl. In embodiments, m is 0. In embodiments, m is 1. In embodiments, m is 1 and R4is F. In embodiments, R6is CH3.

[0450] In embodiments of the compounds of Formula (III), (III-l), or (III-2), n is 0; R2isR2.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0451] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2is

[0452] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2ismIS, wherein the asterisk (*) represents the point of attachment to R2.

[0453] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2is m, wherein the asterisk (*) represents the point of attachment to R2.

[0454] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2isattachment to R2.

[0455] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0456] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2is rN; and isv — 7, wherein the asterisk (*) represents the point of attachment to R2.

[0457] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2iswherein the asterisk (*) represents the point of attachment to R2.

[0458] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2is

[0459] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2is N=N4r Y(R )m\LY A ) — | L YY J*—1—; and ' is, wherein the asterisk (*) represents the point of attachment to R2.

[0460] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2iswherein the asterisk (*) represents the point of attachment to R2.Attorney Docket No.: INMD-209 / 01WO 315953-4493

[0461] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2is

[0462] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2is m, wherein the asterisk (*) represents the point of attachment to R2.

[0463] In embodiments of the compounds of Formula (III), (III-l), or (III-2), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0; R2isof attachment to R2.

[0464] In embodiments of the compounds of Formula (I) or (la), or pharmaceuticallyNHacceptable salt, a stereoisomer, or a deuterated form thereof, R1isF, wherein the asterisk (*) represents the point of attachment to ON=N klNHR2; R2is. In embodiments, R1is. In embodiments, R1isNHAttorney Docket No.: INMD-209 / 01WO 315953-4493

[0465] In embodiments of the compounds of Formula (II-C) or (III-B), or a pharmaceutically is 0, and

[0466] In embodiments of the compounds of Formula (II-C), or a pharmaceutically acceptable

[0467] In embodiments of the compounds of Formula (III-B), or a pharmaceutically acceptable

[0468] In embodiments of the compounds of Formula (II-C) or (III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0, andAttorney Docket No.: INMD-209 / 01WO 315953-4493or

[0469] In embodiments of the compounds of Formula (III-F), or a pharmaceutically acceptable,5. salt, a stereoisomer, or a deuterated form thereof, wherein nis 0, and

[0470] In embodiments of the compounds of Formula (III-I), or a pharmaceutically acceptable R6salt, a stereoisomer, or a deuterated form thereof, wherein nis 0, and NSi;~" N i;

[0471] In embodiments of the compounds of Formula (II-C), (II-D), (III-B), (III-C), (III-D), (Ib-B), (Ic-B), or (Ic-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, n is 0, 1, or 2. In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2. In embodiments, R3is halogen, Ci-6 alkyl or Ci-6 alkylene-OH. In embodiments, R3is F, Cl, CH3, or CH3OH. In embodiments, R3is F, CH3, or CH3OH. In embodiments, m is 0, 1 or 2. In embodiments, m is 0. In embodiments, m is 1. In embodiments, m is 2. R4is halogen, OH, C1-6 haloalkyl or C3-8 cycloalkyl. In embodiments, R4is halogen. In embodiments, R4is F, Cl or Br. In embodiments, R4is F. In embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0 or 1. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, R5is selected from halogen, oxo, C1-6 alkyl or CN. In embodiments, R5is selected from F, CH3 or CN. In embodiments, R6is C1-6 alkyl, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-(N-heterocyclyl) or C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl). InAttorney Docket No.: INMD-209 / 01WO 315953-4493Nembodiments, R6is H, CH3,In embodiments, R6is CH3,. In embodiments, R6is CH3. In embodiments, n is 0 and R6is CH3.

[0472] In embodiments of the compounds of Formula (II-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, Q is CH, CR5or N. In embodiments, Q is CH. In embodiments, Q is CR5. In embodiments, Q is N. In embodiments, n is 0, 1, or 2. In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2. In embodiments, R3is halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHC1-6 alkyl or N(C1-6 alkyl)2. In embodiments, R3is halogen, C1-6 alkyl or C1-6 alkylene-OH. In embodiments, R3is F, Cl, CH3, or CH3OH. In embodiments, R3is F, CH3, or CH3OH. In embodiments, m is 0, 1 or 2. In embodiments, m is 0. In embodiments, m is 1. In embodiments, m is 2. R4is halogen, OH, C1-6 haloalkyl or C3-8 cycloalkyl. In embodiments, R4is halogen. In embodiments, R4is F, Cl or Br. In embodiments, R4is F. In embodiments, p is 0, 1, 2 or 3. In embodiments, p is 0 or 1. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodi...

Claims

Attorney Docket No.: INMD-209 / 01WO 315953-4493CLAIMSWhat is claimed is:

1. A compound of Formula (I):R' ' No L z"^ / (R4)mIA1(i),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:R1is_x1(R3)n-feV / a) ' whereinX1is -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O-, -O-CH2-, -O-CH2-CH2-, -CH2-CH2-O- or -CH2-O-CH2-;X2is -CH2- or -CH2-CH2-; andX3is -NH-, -CH2-NH-, -NH-CH2-, -CH2-CH2-NH-, -NH-CH2-CH2- or -CH2- NH-CH2-; or(R^n-rJ / J^Y4^Y3^yb) ', whereinY1is -CH2-CH2-, -CH2-CH2CH2-, -CH2CH2NH-, -NHCH2CH2-, -CH2O-, - OCH2-, -CH2CH2O- or -OCH2CH2-;Y2is -CH2- or -CH2-CH2-;Y3is absent, -NH-, -CH2-, -CH2-NH- or -NH-CH2-; andY4is absent, -CH2- or -O-;Ring A is arylene, heteroarylene or heterocyclylene;R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;Attorney Docket No.: INMD-209 / 01WO 315953-4493or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;R3is selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHCI-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;R4is selected from halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(CI-6 alkyl)2, Ci-4alkylene-NH-Ci-6 alkyl or Ci-4alkylene-N(Ci-6 alkyl)2;each R5is independently halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl,I— L— ( )heterocyclyl heteroaryl, or1, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(CI-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(CI-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH;provided that the compound is not any compounds disclosed in patent applications having publication numbers: CN114106005, W02016038007, WO2016016242 W02014140081, W02024094208, W02022053019, W02022053019, US 20180125865, WO2016139355, WO2015032943, WO2015032942, W02014140078, W02014140075, W02014140091, WO2013041497, or WO2012119941.Attorney Docket No.: INMD-209 / 01WO 315953-44932. The compound of claim 1 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound is a compound of Formula (la):H N NR2or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein X1is -CH2-, -CH2-CH2-, -CH2CH2CH2-, -CH2-O-, -O-CH2-, -O-CH2-CH2-, -CH2-CH2-O-or -CH2-O-CH2-;X2is -CH2- or -CH2-CH2-;X3is -NH-, -CH2-NH-, -NH-CH2-, -CH2-CH2-NH-, -NH-CH2-CH2- or -CH2-NH-CH2-; R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;R3is selected from halogen, C1-6 alkyl, C1-6 alkylene-OH, OH, CN, OC1-6 alkyl, SC1-6 alkyl, NH2, NHCI-6 alkyl, N(CI-6alkyl)2orNHC(O)Ci-6alkyl;R4is selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;each R5is independently halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl,L— ET)heterocyclyl heteroaryl, or5, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl,Attorney Docket No.: INMD-209 / 01WO 315953-4493cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andeach R6is independently H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH;provided that:Attorney Docket No.: INMD-209 / 01WO 315953-44933. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has a structure of Formula (II):Attorney Docket No.: INMD-209 / 01WO 315953-4493or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has a structure of Formula (II-B):(II-B),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has a structure of Formula (II-C):(R3)n(II-C),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein p is 0, 1, 2, or 3.

6. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has a structure of Formula (II-D):(II-D), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Q is CH, CR5aor N, p is 0, 1, 2, or 3, and wherein R5ais halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-Attorney Docket No.: INMD-209 / 01WO 315953-44936 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl,|— L— (T)S(=O)2alkyl, heterocyclyl, heteroaryl, or•, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl.

7. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has a structure of Formula (III):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

8. The compound of any one of claims 1, 2 and 7, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has a structure of Formula (III-A):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

9. The compound of any one of claims 1, 2, 7, and 8, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has a structure of Formula (III-B):Attorney Docket No.: INMD-209 / 01WO 315953-4493(III-B), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, and wherein p is 0, 1, 2, or 3.

10. The compound of any one of claims 1, 2, 7, and 8, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has a structure of Formula (III-F):(III-F), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Q is CH, CR5aor N, p is 0, 1, 2, or 3, and R5ais halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl,L— (T)heterocyclyl heteroaryl, or’, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl.

11. The compound of any one of claims 1, 2 and 7, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has a structure of Formula (III-G):Attorney Docket No.: INMD-209 / 01WO 315953-4493(III-G),or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

12. The compound of any one of claims 1, 2, 7, and 11, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has a structure of Formula (III-H):(III-H), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, and wherein p is 0, 1, 2, or 3.

13. The compound of any one of claims 1, 2, 7, and 11, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound has a structure of Formula (III-I):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Q is CH, CR5aor N, p is 0, 1, 2, or 3, and R5ais halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2alkyl,L— ( )heterocyclyl heteroaryl, or1, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted withAttorney Docket No.: INMD-209 / 01WO 315953-44931-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl.

14. The compound of any one of claims 6, 10, 12, and 13, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Q is CH, CF, or N.

15. The compound of any one of claims 6, 10, 12, 13, and 14, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Q is CH.

16. The compound of any one of claims 6, 10, 12, 13, and 14, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Q is N.

17. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer,or a deuterated form thereof, wherein R1is(R3)n',, ', ' or '.

18. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer,_X1or a deuterated form thereof, wherein R1is19. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer,(R3)nor a deuterated form thereof, wherein R1is '.

20. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer,Nor a deuterated form thereof, wherein R1isN21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0.Attorney Docket No.: INMD-209 / 01WO 315953-449322. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 1.

23. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 2.

24. The compound of any one of claims 1-20,22 and 23, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R3is halogen, Ci-6 alkyl, or Ci-6 alkylene-OH.

25. The compound of any one of claims 1-20 and 22-24, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R3is F, Cl, CH3, or CH3OH.

26. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer,27. The compound of any one of claims 1, 2 and 26, or a pharmaceutically acceptable salt,a stereoisomer, or a deuterated form thereof, wherein R1isAttorney Docket No.: INMD-209 / 01WO 315953-449328. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:X1is -CH2-CH2- or -CH2-CH2-CH2-;X2is -CH2- or -CH2-CH2-; and / orX3is -NH- or -CH2-NH-*;wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I) or (la).

29. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:X1is -CH2-CH2- and X2is -CH2-CH2-;X1is -CH2-CH2- and X3is -CH2-NH-*;X2is -CH2-CH2- and X3is -CH2-NH-*; orX1is -CH2-CH2-, X2is -CH2-CH2-, and X3is -CH2-NH-*;wherein the asterisk (*) represents the point of attachment to the quaternary carbon atom adjacent to the carbonyl group of Formula (I) or (la).

30. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:X1is -CH2-CH2-CH2- and X2is -CH2-;X1is -CH2-CH2-CH2- and X3is -NH-;X2is -CH2- and X3is -NH-; orX1is -CH2-CH2-CH2-, X2is -CH2-, and X3is -NH-.

31. The compound of any one of claims 1, 2, and 26-30, or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, whereinNHAttorney Docket No.: INMD-209 / 01WO 315953-449332. The compound of any one of claims 1, 2, and 26-28 and 30-31, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, wherein33. The compound of any one of claims 1, 2, 26-28, 29, and 31, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, whereinNH34. The compound of any one of claims 1, 2, 27-28, and-33, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, wherein35. The compound of any one of claims 1-34, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 0.

36. The compound of any one of claims 1-34, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 1.

37. The compound of any one of claims 1-34, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 2.

38. The compound of any one of claims 1-3, 7, and 17-37, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is arylene.

39. The compound of any one of claims 1-3, 7, and 17-38, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is phenylene.Attorney Docket No.: INMD-209 / 01WO 315953-449340. The compound of any one of claims 1-3, 7, and 17-39, or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, wherein41. The compound of any one of claims 1-3, 7, and 17-40, or a pharmaceutically acceptable (R4)m I— ( A ) — | i AA i salt, a stereoisomer, or a deuterated form thereof, whereinis?— J 42. The compound of any one of claims 1-40, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is halogen.

43. The compound of any one of claims 1-42, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is F.

44. The compound of any one of claims 1-3, 7, 17-40, and 42-43, or a pharmaceutically (R4)m I— ( k ) — | acceptable salt, a stereoisomer, or a deuterated form thereof, wherein' is F45. The compound of any one of claims 1-3, 7, 17-40, and 42-44, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, wherein, wherein the asterisk (*) represents the point of attachment to R2.

46. The compound of any one of claims 1-3, 7, and 17-37, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is heteroarylene.

47. The compound of any one of claims 1-3, 7, and 17-37, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is 5- or 6-membered heteroarylene.Attorney Docket No.: INMD-209 / 01WO 315953-449348. The compound of any one of claims 1-3, 7, and 17-37, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is 5-membered heteroarylene with 1, 2, or 3 heteroatoms selected from N, O, or S.

49. The compound of any one of claims 1-3, 7, 17-37, and 48, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is thiazolylene.

50. The compound of any one of claims 1-3, 7, 17-37, and 46-49, or a pharmaceutically (R4)m ( A ) — | acceptable salt, a stereoisomer, or a deuterated form thereof, whereinisAH51. The compound of any one of claims 1-3, 7, 17-37, and 46-50, or a pharmaceutically (R4)m FA acceptable salt, a stereoisomer, or a deuterated form thereof, whereinA) — IisANH, wherein the asterisk (*) represents the point of attachment to R2.

52. The compound of any one of claims 1-3, 7, 17-37, and 46, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is bicyclic heteroarylene.

53. The compound of any one of claims 1-3, 7, 17-37, 46 and 52, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A isorwherein X is selected from O, S, NH or N(CI-6 alkyl).

54. The compound of claim 53, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein X is O.Attorney Docket No.: INMD-209 / 01WO 315953-449355. The compound of any one of claims 1-3, 7, 17-37, 46 and 52, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is°"'l^Xx|orFwherein the asterisk (*) represents the point of attachment to R2.

56. The compound of any one of claims 1-3, 7, 17-37, 46, 52, and 55, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is57. The compound of any one of claims 1-3, 7, 17-37, 46, and 52-54, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, wherein58. The compound of any one of claims 1-3, 7, 17-37, 46, and 52-54, or a pharmaceutically (R4)mA) — I acceptable salt, a stereoisomer, or a deuterated form thereof, whereinis •> *F, wherein the asterisk (*) represents the point of attachment to R2.

59. The compound of any one of claims 1-4, 7, 8, and 17-58, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-209 / 01WO 315953-4493ring B and ring C are each independently an aromatic ring optionally substituted with 1-3 group selected from R5or R6;ring D is a cycloalkyl, cycloalkenyl, heterocyclyl or heterocycloalkenyl optionally substituted with 1-3 group selected from R5or R6;ring E is aryl, heteroaryl or heterocyclyl;U and V are each independently CH2, C(=O), O or NR6;W is N or CH;p is 0, 1, 2 or 3;q and r are each independently 0, 1, 2 or 3, provided that q and r are not both 0;R5is selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl, heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; and R6is selected from H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(CI-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH;provided that:Attorney Docket No.: INMD-209 / 01WO 315953-449360. The compound of any one of claims 1-4, 7, 8, and 17-59, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-209 / 01WO 315953-449361. The compound of any one of claims 1-60, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R6is H, Ci-6 alkyl, deuterated Ci-6 alkyl, Ci-6 alkylene-NH2, Ci-6 alkylene-NH(Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-NH(CI-6 alkylene-O-Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), Ci-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl.

62. The compound of any one of claims 1-61, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R6is H, C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(CI-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl or heterocyclyl.

63. The compound of any one of claims 1-62, or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R6is CH3, CD3, '64. The compound of any one of claims 1-63, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R6is CH3.

65. The compound of any one of claims 5-6, 9-10, and 12-64, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein p is 0, 1, or 2.

66. The compound of any one of claims 5-6, 9-10, and 12-64, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein p is 0 or 1.

67. The compound of any one of claims 5-6, 9-10, and 12-64, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein p is 0.

68. The compound of any one of claims 1-67, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R5is halogen.

69. The compound of any one of claims 1-68, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R5is F.Attorney Docket No.: INMD-209 / 01WO 315953-4493 70. The compound of any one of claims 1-3, 7, 8, and 17-59, or a pharmaceuticallyThe compound of any one of claims 1-3, 7, 8, and 17-59, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-209 / 01WO 315953-449372. The compound of any one of claims 1-3, 7, 8, and 17-59, or a pharmaceutically o acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2isAttorney Docket No.: INMD-209 / 01WO 315953-449373. The compound of any one of claims 1-3, 7, 8, and 17-59, or a pharmaceutically Oacceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2is =N N=N74. The compound of any one of claims 1-3, 7, 8, 17-59, and 73, or a pharmaceutically Oacceptable salt, a stereoisomer, or a deuterated form thereof, whereinR2is 75. The compound of any one of claims 1-3, 7, 8, 17-59, 70, and 73, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, whereinR2is 76. The compound of any one of claims 1-3, 7, 8, 17-59, 70, and 73, or a pharmaceutically N=Nacceptable salt, a stereoisomer, or a deuterated form thereof, whereinR2isAttorney Docket No.: INMD-209 / 01WO 315953-449377. The compound of any one of claims 1-3, 7, 8, 17-59, 70, and 73, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, whereinR2is78. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer,79. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer,or a deuterated form thereof, whereinR1is80. The compound of any one of claims 1, 2 and 79, or a pharmaceutically acceptable salt,a stereoisomer, or a deuterated form thereof, wherein R1is and R6is Ci-6 alkyl.

81. The compound of any one of claims 1, 2, 79 and 80, or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, wherein R1isAttorney Docket No.: INMD-209 / 01WO 315953-449382. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer,or a deuterated form thereof, whereinR1is83. The compound of any one of claims 1, 2, and 82, or a pharmaceutically acceptable salt,a stereoisomer, or a deuterated form thereof, wherein R1is R6is Ci-6 alkyl.

84. The compound of any one of claims 1, 2, 82, and 83, or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, wherein R1is85. The compound of any one of claims 1, 2, and 84, or a pharmaceutically acceptable salt,a stereoisomer, or a deuterated form thereof, wherein R1is86. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, a stereoisomer, or a F— (R5)P deuterated form thereof, wherein R1is and R2is, orAttorney Docket No.: INMD-209 / 01WO 315953-4493 N=N87. The compound of any one of claims 1, 2, and 86, or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R1isand each R6is independently Ci-6 alkyl.

88. The compound of any one of claims 1, 2, 86, and 87, or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, wherein R1isN=N89. The compound of any one of claims 1, 2, and 88, or a pharmaceutically acceptable salt,90. The compound of any one of claims 1, 2, and 88, or a pharmaceutically acceptable salt,Attorney Docket No.: INMD-209 / 01WO 315953-449391. The compound of any one of claims 1, 2, and 88, or a pharmaceutically acceptable salt,L^J I?' ''JL a stereoisomer, or a deuterated form thereof, wherein R1isHorH, and R2is N=NQf92. The compound of any one of claims 5, 6, 9, 10, 12 and 13, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0, m is 0, p is 0, and R6is Ci-3 alkyl.

93. The compound of any one of claims 5, 6, 9, 10, 12, 13, and 90, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0, m is 0, p is 0, and R6is CH3.

94. The compound of any one of claims 6, 10, and 13, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0, m is 0, p is 0, Q is CH, and R6is CH3.

95. The compound of any one of claims 6, 10, and 13, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0, m is 0, p is 0, Q is N, and R6is CH3.

96. The compound of any one of claims 5, 6, 9, 10, 12, and 13, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0, m is 1, R4is halo, p is 0, and R6is Ci-6 alkyl.

97. The compound of any one of claims 5, 6, 9, 10, 12, 13, and 96, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0, m is 1, R4is halo, p is 0, and R6is CH3.

98. The compound of claim 10, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0, m is 1, R4is halo, p is 0, Q is N, and R6is CH3.Attorney Docket No.: INMD-209 / 01WO 315953-449399. The compound of any one of claims 96-98, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is F.

100. The compound of claim 3 or 7, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein::4)mm is 0 or 1;n is 0;F\_N1 KiR4is halogen; andR6is H or Ci-3 alkyl.

101. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring.

102. The compound of any one of claims 1-4 and 101, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2and one R4together with the atoms they are attached to form a bicyclic ring wherein the ring is cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl.

103. The compound of any one of claims 1-4, 101, and 102, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2and one R4together with the atoms they are attached to form a heteroaryl ring.

104. The compound of any one of claims 1-4 and 101-103, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2and one R4together with the atoms they are attached to form a bicyclic heteroaryl ring.

105. The compound of any one of claims 1-4 and 101-104, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2and one R4together with the atoms they are attached to form a tricyclic heteroaryl ring.Attorney Docket No.: INMD-209 / 01WO 315953-4493106. The compound of any one of claims 1-4 and 101-105, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2and one R4together with the atoms they are attached to form a tetracyclic heteroaryl ring.

107. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, am is 0, 1, 2 or 3;each of pl and p2 is 0, 1, 2 or 3, provided that the sum of pl and p2 is 0, 1, 2 or 3; each of q and r is 0, 1, 2 or 3, provided that q and r is not 0 at the same time;U and V are each independently CH2, C(=O), O or NR6;Z is O, CH2O, OCH2, CH2 or CH2CH2;R4ais selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andR6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2,Attorney Docket No.: INMD-209 / 01WO 315953-4493alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, Ci-6 alkyl, OCi-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

108. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, whereinwhereinm is 0, 1, 2 or 3;p is 0, 1, 2 or 3;Z is O, CH2O, OCH2, CH2 or CH2CH2;R4ais selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2; andR5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl.

109. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein, whereinm is 0, 1, 2 or 3;Attorney Docket No.: INMD-209 / 01WO 315953-4493p is 0, 1, or 2;each of q and r is 0, 1, 2 or 3, provided that q and r is not 0 at the same time;U and V are each independently CH2, C(=O), O or NR6;Z is O, CH2O, OCH2, CH2 or CH2CH2;R4ais selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andR6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

110. The compound of any one of claims 107-109, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Z is CH2O or OCH2.

111. The compound of any one of claims 1-3, 107, and 110, or a pharmaceutically acceptable,(Rsalt, a stereoisomer, or a deuterated form thereof, whereinAttorney Docket No.: INMD-209 / 01WO 315953-4493112. The compound of any one of claims 107-111, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 0.

113. The compound of any one of claims 107-111, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 1.

114. The compound of any one of claims 107-109 and 113, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4ais halo.

115. The compound of any one of claims 107-111, 113, and 114, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4ais F.

116. The compound of any one of claims 107-115, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein p is 0.

117. The compound of any one of claims 107-115, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein p is 1.

118. The compound of any one of claims 104-115 and 117, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R5is halo, heterocyclyl or CN.

119. The compound of any one of claims 104-115, 117, and 118, or a pharmaceutically 0acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R5is F,or CN.

120. The compound of any one of claims 104-119, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R6is H, Ci-6 alkyl or heterocyclyl.Attorney Docket No.: INMD-209 / 01WO 315953-4493121. The compound of any one of claims 104-120, or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R6is methylor122. The compound of any one of claims 104-121, or a pharmaceutically acceptable salt, a123. The compound of claim 1, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound is a compound of Formula (lb):or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Y1is -CH2-CH2-, -CH2-CH2CH2-, -CH2CH2NH-, -NHCH2CH2-, -CH2O-, -OCH2-, - CH2CH2O- or -OCH2CH2-;Y2is -CH2- or -CH2-CH2-;Y3is absent, -NH-, -CH2-, -CH2-NH- or -NH-CH2-;Y4is absent, -CH2- or -O-;Attorney Docket No.: INMD-209 / 01WO 315953-4493n is 0, 1 or 2;R3is selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHCI-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;Ring A is arylene, heteroarylene or heterocyclylene;m is 0, 1, 2, or 3;R4is selected from halogen, OH, Ci-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, -NH2, -NHC1-6 alkyl, -N(C1-6 alkyl)2, Ci-4 alkylene-NH-Ci-6 alkyl or Ci-4alkylene-N(Ci-6 alkyl)2;R2is 6-18 membered aryl optionally substituted with 1-5 groups independently selected from R5or R6, 5-12 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O, wherein the heterocyclyl is optionally substituted with 1-5 groups independently selected from R5or R6, or 5-20 membered heteroaryl containing 1-3 heteroatoms selected from N, S or O, wherein the heteroaryl is optionally substituted with 1-5 groups independently selected from R5or R6;or R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein the ring is optionally substituted with 1-5 groups independently selected from R5or R6;R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(CI-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl L— ( )heteroaryl, or1, wherein L is C1-6 alkylene, O, NH or S(=O)2, and ring E is cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andR6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(CI-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3Attorney Docket No.: INMD-209 / 01WO 315953-4493groups selected from halogen, CN, OH, Ci-6 alkyl, OCi-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH;124. The compound of claim 1 or 123, or a pharmaceutically acceptable salt, a stereoisomer,125. The compound of claim 1 or 123, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Y2is CH2CH2.

126. The compound of claim 1 or 123, or a pharmaceutically acceptable salt, a stereoisomer,or a deuterated form thereof, wherein127. The compound of claim 1 or 123, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Y4is absent or O.

128. The compound of any one of claims 1 and 123-127, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0.Attorney Docket No.: INMD-209 / 01WO 315953-4493129. The compound of claim 1 or 123, or a pharmaceutically acceptable salt, a stereoisomer,130. The compound of any one of claims 1, 123, and 129, or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, wherein131. The compound of any one of claims 123-130, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is arylene.

132. The compound of any one of claims 123-131, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is phenylene.

133. The compound of any one of claims 123-132, or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein ring A is.

134. The compound of any one of claims 123-130, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is heteroarylene.

135. The compound of any one of claims 123-130 and 134, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is bicyclic heteroarylene.Attorney Docket No.: INMD-209 / 01WO 315953-4493136. The compound of any one of claims 123-130, 134, and 135, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A iswherein X is selected from O, S, NH or N(CI-6 alkyl).

137. The compound of claim 136, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein X is O.

138. The compound of any one of claims 123-130 and 134-137, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A isor wherein the asterisk (*) represents the point of attachment to R2.

139. The compound of any one of claims 123-130 and 134-137, or a pharmaceuticallyrA acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is140. The compound of any one of claims 123-139, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 0.

141. The compound of any one of claims 123-139, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 1.

142. The compound of any one of claims 123-139, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 2.

143. The compound of any one of claims 123-139, 141 and 142, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is halo.

144. The compound of any one of claims 123-139 and 141-143, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is F.Attorney Docket No.: INMD-209 / 01WO 315953-4493145. The compound of any one of claims 123-130, or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein146. The compound of any one of claims 123-130 and 145, or a pharmaceutically acceptable (R4)m Fsalt, a stereoisomer, or a deuterated form thereof, whereinwherein the asterisk (*) represents the point of attachment to R2.

147. The compound of any one of claims 123-130, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein148. The compound of any one of claims 123-130 and 147, or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, whereinwherein the asterisk (*) represents the point of attachment to R2.ring B and ring C are each independently an aromatic ring optionally substituted with 1-3 group selected from R5or R6;ring D is a cycloalkyl, cycloalkenyl, heterocyclyl or heterocycloalkenyl optionally substituted with 1-3 group selected from R5or R6;U and V are each independently CH2, C(=O), O or NR6;Attorney Docket No.: INMD-209 / 01WO 315953-4493W is N or CH;p is 0, 1, 2 or 3;q and r are each independently 0, 1, 2, provided that q and r are not both 0;R5is selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl or heterocyclyl;R6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, -COC1-6 alkyl, C2-6 alkenyl, C2-6alkynyl, C3-6 cycloalkyl or 3-8 membered heterocyclyl containing 1-3 heteroatoms selected from N, S or O.

150. The compound of any one of claims 123-149, or a pharmaceutically acceptable salt, a O(R5)P< J stereoisomer, or a deuterated form thereof, wherein R2isring E is aryl, heteroaryl or heterocyclyl;U and V are each independently CH2, C(=O), O or NR6;X is CH2orNR6;W is N or CH;Attorney Docket No.: INMD-209 / 01WO 315953-4493p is 0, 1, 2 or 3;q and r are each independently 0, 1, 2, provided that q and r are not both 0;R5is selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andR6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

151. The compound of any one of claims 123-150, or a pharmaceutically acceptable salt, aAttorney Docket No.: INMD-209 / 01WO 315953-4493152. The compound of any one of claims 123-148, or a pharmaceutically acceptable salt, a U-V-R6stereoisomer, or a deuterated form thereof, wherein R2is153. The compound of any one of claims 123-148 and 152, or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, wherein R2is154. The compound of any one of claims 123-153, or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein R2is155. The compound of any one of claims 123-148, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2and one R4together with the atoms they are attached to form a cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring.

156. The compound of any one of claims 123-148 and 155, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2and one R4together with the atoms they are attached to form a bicyclic ring wherein the ring is cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl.Attorney Docket No.: INMD-209 / 01WO 315953-4493157. The compound of any one of claims 123-148, 155, and 156, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2and one R4together with the atoms they are attached to form a heteroaryl ring.

158. The compound of any one of claims 123-148 and 155-157, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2and one R4together with the atoms they are attached to form a bicyclic heteroaryl ring.

159. The compound of any one of claims 123-148 and 155-158, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2and one R4together with the atoms they are attached to form a tricyclic heteroaryl ring.

160. The compound of any one of claims 123-148 and 155-159, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2and one R4together with the atoms they are attached to form a tetracyclic heteroaryl ring.

161. The compound of any one of claims 123-148 and 155-160, or a pharmaceuticallym is 0, 1, 2 or 3;each of pl and p2 is 0, 1, 2 or 3, provided that the sum of pl and p2 is 0, 1, 2 or 3; each of q and r is 0, 1, 2 or 3, provided that q and r is not 0 at the same time;U and V are each independently CH2, C(=O), O or NR6;Z is O, CH2O, OCH2, CH2 or CH2CH2;Attorney Docket No.: INMD-209 / 01WO 315953-4493R4ais selected from halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl or heteroaryl; wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andR6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl; wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

162. The compound of any one of claims 123-148 and 155-160, or a pharmaceutically z ^-^ / (R4)mIA1 p2 acceptable salt, a stereoisomer, or a deuterated form thereof, whereinis(R4a)m(R5)Pz, whereinm is 0, 1, 2 or 3;p is 0, 1, 2 or 3;Z is O, CH2O, OCH2, CH2 or CH2CH2;R4ais selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2; andR5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclylAttorney Docket No.: INMD-209 / 01WO 315953-4493or heteroaryl, wherein the alkyl, OCi-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl.

163. The compound of any one of claims 123-148 and 155-160, or a pharmaceuticallyIA1 acceptable salt, a stereoisomer, or a deuterated form thereof, whereinism is 0, 1, 2 or 3;p is 0, 1, or 2;each of q and r is 0, 1, 2 or 3, provided that q and r is not 0 at the same time;U and V are each independently CH2, C(=O), O or NR6;Z is O, CH2O, OCH2, CH2 or CH2CH2;R4ais selected from halogen, OH, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl or heteroaryl, wherein the alkyl, OC1-6 alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups within R5are optionally substituted with 1-3 groups selected from halogen, CN, OH, NH2, OC1-6 alkyl, C1-6 alkyl, COOH, cycloalkyl, aryl, heterocyclyl or heteroaryl; andR6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl, wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3Attorney Docket No.: INMD-209 / 01WO 315953-4493groups selected from halogen, CN, OH, Ci-6 alkyl, OCi-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH.

164. The compound of any one of claims 161-163, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein Z is CH2O or OCH2.

165. The compound of any one of claims 123-148, 161, and 164, or a pharmaceutically / _ X)m166. The compound of any one of claims 161-165, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 0.

167. The compound of any one of claims 161-165, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 1.

168. The compound of any one of claims 161-165 and 167, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4ais halo.

169. The compound of any one of claims 161-165, 167, and 168, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4ais F.

170. The compound of any one of claims 123-169, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein p is 0.

171. The compound of any one of claims 123-169, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein p is 1.

172. The compound of any one of claims 123-169 and 171, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R5is halo, heterocyclyl or CN.Attorney Docket No.: INMD-209 / 01WO 315953-4493173. The compound of any one of claims 123-169, 171, and 172, or a pharmaceutically 0acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R5is F,— or CN.

174. The compound of any one of claims 123-140, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R6is H, Ci-6 alkyl or heterocyclyl.

175. The compound of any one of claims 123-141, or a pharmaceutically acceptable salt, a 0stereoisomer, or a deuterated form thereof, wherein R6is methylor.

176. The compound of any one of claims 123-165, wherein177. The compound of claim 1, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound is a compound of Formula (Ic):Attorney Docket No.: INMD-209 / 01WO 315953-4493or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:Ring A is arylene, heteroarylene or heterocyclylene;n is 0, 1 or 2;m is 0, 1, 2, 3 or 4;R3is selected from halogen, Ci-6 alkyl, Ci-6 alkylene-OH, OH, CN, OCi-6 alkyl, SCi-6 alkyl, NH2, NHCI-6 alkyl, N(C1-6 alkyl)2or NHC(O)C1-6 alkyl;R4is selected from halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(CI-6 alkyl)2, Ci-4alkylene-NH-Ci-6 alkyl or Ci-4alkylene-N(Ci-6 alkyl)2;Attorney Docket No.: INMD-209 / 01WO 315953-4493m is 0, 1, 2 or 3;p is 0, 1 or 2;R4ais selected from halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, C1-4 alkylene-NH-C1-6 alkyl or C1-4 alkylene-N(C1-6 alkyl)2;R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl or heterocyclyl;R6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkylene-O-Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl; wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(CI-6 alkyl), N(C1-6 alkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl;provided that:Attorney Docket No.: INMD-209 / 01WO 315953-4493\ and178. The compound of claim 177, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound is a compound of Formula (Ic-A);or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

179. The compound of claim 177, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound is a compound of Formula (Ic-B):(R )Por a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

180. The compound of claim 177, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein the compound is a compound of Formula (Ic-C):Attorney Docket No.: INMD-209 / 01WO 315953-4493(Ic-C), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof.

181. The compound of claim 177, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is arylene.

182. The compound of claim 177 or 181, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is phenylene.

183. The compound of any one of claims 177, 181, and 182, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is.

184. The compound of claim 177, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is heteroarylene.

185. The compound of claim 177 or 184, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A is bicyclic heteroarylene.

186. The compound of any one of claims 177, 184, and 185, or a pharmaceuticallyacceptable salt, a stereoisomer, or a deuterated form thereof, wherein ringA iswherein X is selected from O, S, NH or N(CI-6 alkyl).

187. The compound of claim 186, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein X is O.Attorney Docket No.: INMD-209 / 01WO 315953-4493188. The compound of any one of claims 177 and 184-187, or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, wherein ring A isFwherein the asterisk (*) represents the point of attachment to R2.

189. The compound of any one of claims 177 and 184-188, or a pharmaceutically acceptablesalt, a stereoisomer, or a deuterated form thereof, wherein ring A is HOOH 190. The compound of any one of claims 177-189, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 0.

191. The compound of any one of claims 177-189, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 1.

192. The compound of any one of claims 177-189, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein m is 2.

193. The compound of any one of claims 177-189, 191, and 192, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is halo.

194. The compound of any one of claims 177-189 and 191-193, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein R4is F.

195. The compound of any one of claims 177 and 181-183, or a pharmaceutically acceptable (R4)m Fsalt, a stereoisomer, or a deuterated form thereof, wherein196. The compound of any one of claims 177, 181-183 and 195, or a pharmaceutically (R4)mH \A) — I acceptable salt, a stereoisomer, or a deuterated form thereof, whereinis F, wherein the asterisk (*) represents the point of attachment to R2.Attorney Docket No.: INMD-209 / 01WO 315953-4493197. The compound of any one of claims 177 and 184-188, or a pharmaceutically acceptable198. The compound of any one of claims 177, 184-188 and 197, or a pharmaceutically (R4)m ( A ) — | acceptable salt, a stereoisomer, or a deuterated form thereof, whereinis HZQJF, wherein the asterisk (*) represents the point of attachment to R2.

199. The compound of any one of claims 177, 178, and 181-198, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein:p is 0, 1, 2 or 3;R5is selected from halogen, oxo, Ci-6 alkyl, OCi-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl or heterocyclyl;R6is selected from H, C1-6 alkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), C1-6 alkylene-Attorney Docket No.: INMD-209 / 01WO 315953-4493heterocyclyl, C(=0)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl; wherein the C1-6 alkyl, NH2, N(C1-6 alkyl)2, alkenyl, alkynyl, cycloalkyl and heterocyclyl within R6is optionally substituted with 1-3 groups selected from halogen, CN, OH, C1-6 alkyl, OC1-6 alkyl, NH2, NH(C 1-6 alkyl), N(Ci-ealkyl)2, cycloalkyl, aryl, heterocyclyl, heteroaryl or COOH; andR6ais C2-6 alkyl, C3-6 cycloalkyl, 3-8 membered heterocyclyl, C1-6 alkylene-NH2, C1-6 alkylene-N(Ci-6 alkyl)2, C1-6 alkylene-NH(Ci-6 alkyl), C1-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl) or C1-6 alkylene-heterocyclyl.

200. The compound of any one of claims 177, 178, and 181-199, or a pharmaceutically Oacceptable salt, a stereoisomer, or a deuterated form thereof, wherein R2is201. The compound of any one of claims 177, 178, and 181-200, or a pharmaceuticallyAttorney Docket No.: INMD-209 / 01WO 315953-4493202. The compound of any one of claims 177, 178, and 181-201, or a pharmaceutically N=Nacceptable salt, a stereoisomer, or a deuterated form thereof, whereinR2is 203. The compound of claim 180, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0, m is 0, p is 0, and R6is C3 alkyl.

204. The compound of claim 180 or 203, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0, m is 0, p is 0, and R6is CH3.

205. The compound of claim 180, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0, m is 1, R4is halo, p is 0, and R6is C1-6 alkyl.

206. The compound of claim 180 or 205, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein n is 0, m is 1, R4is halo, p is 0, and R6is CH3.Attorney Docket No.: INMD-209 / 01WO 315953-4493207. The compound of claim 180 or 206, or a pharmaceutically acceptable salt, astereoisomer, or a deuterated form thereof, wherein nis 0, and208. The compound of any one of claims 177, 178, and 181-198, or a pharmaceuticallywherein m is 0, 1, 2 or 3;p is 0, 1, 2 or 3;R4ais selected from halogen, OH, Ci-6 alkyl, Ci-6 haloalkyl, C3-8 cycloalkyl, OC1-6 alkyl, OC1-6 alkylene-aryl, OC1-6 haloalkyl, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, Ci-4alkylene-NH-Ci-6 alkyl or Ci-4alkylene-N(Ci-6 alkyl)2.R5is selected from halogen, oxo, C1-6 alkyl, OC1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, CN, OH, NH2, NHC1-6 alkyl, N(C1-6 alkyl)2, COOH, COC1-6 alkyl, COOC1-6 alkyl, CONHC1-6 alkyl, CON(C1-6 alkyl)2, NHCOC1-6 alkyl, SC1-6 alkyl, S(=O)2 alkyl, heterocyclyl; andAttorney Docket No.: INMD-209 / 01WO 315953-4493R6is selected from H, Ci-6 alkyl, Ci-6 alkylene-NH2, Ci-6 alkylene-NH(Ci-6 alkyl), Ci-6 alkylene-N(Ci-6 alkyl)2, Ci-6 alkylene-N(Ci-6 alkylene-O-Ci-6 alkyl)(Ci-6 alkyl), Ci-6 alkylene-heterocyclyl, C(=O)Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or heterocyclyl.

209. The compound of any one of claims 177, 178, 181-198, and 208, or a pharmaceutically210. A compound selected from Table A, Table B, or Table C, or a pharmaceutically acceptable salt, a stereoisomer, a racemic form, or a deuterated form thereof.

211. A pharmaceutical composition comprising an effective amount of a compound of any one of claims 1-210, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof and a pharmaceutically acceptable adjuvant, diluent or carrier.

212. A method for treating an obstructive disease of the airway in a patient in need thereof, comprising, administering to the patient an effective amount of a compound of any one of claims 1-210, or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.

213. The method of claim 212, wherein the obstructive disease of the airway is asthma, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, cystic fibrosis (CF),Attorney Docket No.: INMD-209 / 01WO 315953-4493bronchiectasis, sarcoidosis, alpha-1 antitrypsin (Al AT) deficiency, farmer’s lung and related diseases, hypersensitivity pneumonitis, pulmonary fibrosis, complications of lung transplantation, vasculitic and thrombotic disorders of the lung vasculature, pulmonary hypertension, antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, iatrogenic cough, acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever), nasal polyposis; acute viral infection including the common cold, and infection due to a respiratory virus, acute lung injury, or acute respiratory distress syndrome (ARDS).

214. The method of claim 213, wherein the obstructive disease of the airway is asthma.

215. The method of claim 213, wherein the obstructive disease of the airway is acute respiratory distress syndrome (ARDS).

216. The method of claim 213, wherein the obstructive disease of the airway is bronchitis.

217. The method of claim 213, wherein the obstructive disease of the airway is pulmonary fibrosis.

218. The method of claim 213, wherein the obstructive disease of the airway is emphysema.

219. The method of claim 213, wherein the obstructive disease of the airway is cystic fibrosis (CF).

220. The method of claim 213, wherein the obstructive disease of the airway is bronchiectasis.

221. The method of claim 213, wherein the obstructive disease of the airway is sarcoidosis 222. The method of claim 213, wherein the obstructive disease of the airway is alpha-1 antitrypsin (A1AT) deficiency.

223. The method of claim 213, wherein the obstructive disease of the airway is farmer’s lung.

224. The method of claim 213, wherein the obstructive disease of the airway is hypersensitivity pneumonitis.

225. The method of claim 213, wherein the obstructive disease of the airway is a complication of lung transplantation.

226. The method of claim 213, wherein the obstructive disease of the airway is a vasculitic or thrombotic disorder of the lung vasculature.Attorney Docket No.: INMD-209 / 01WO 315953-4493227. The method of claim 213, wherein the obstructive disease of the airway is pulmonary hypertension.

228. The method of claim 213, wherein the obstructive disease of the airway is iatrogenic cough.

229. The method of claim 213, wherein the obstructive disease of the airway is acute rhinitis.

230. The method of claim 213, wherein the obstructive disease of the airway is chronic rhinitis.

231. The method of claim 213, wherein the obstructive disease of the airway is rhinitis medicamentosa or vasomotor rhinitis.

232. The method of claim 213, wherein the obstructive disease of the airway is nasal polyposis.

233. The method of claim 213, wherein the obstructive disease of the airway is COPD.

234. The method of claim 214, wherein the asthma is neutrophilic, bronchial, allergic, intrinsic, extrinsic, exercise-induced or drug-induced asthma.

235. The method of claim 234, wherein the bronchitis is infectious bronchitis or eosinophilic bronchitis.

236. The method of claim 217, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis, cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonia, or fibrosis complicating anti-neoplastic therapy or chronic infection.

237. The method of claim 220, wherein the bronchiectasis is non-cystic fibrosis bronchiectasis (NCFBE).

238. The method of claim 220, wherein the bronchiectasis is associated with cystic fibrosis.

239. The method of claim 227, wherein the pulmonary hypertension is pulmonary arterial hypertension.

240. The method of claim 227, wherein the pulmonary hypertension is pulmonary hypertension due to left heart disease.

241. The method of claim 227, wherein the pulmonary hypertension is pulmonary hypertension associated with chronic lung disease.Attorney Docket No.: INMD-209 / 01WO 315953-4493242. A method for treating cystic fibrosis in a patient in need thereof, comprising, administering to the patient an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.

243. The method of claim 242, wherein the treating comprises improving the lung function of the patient, as compared to the lung function of the patient prior to treatment.

244. The method of claim 243, wherein improving lung function of the patient comprises increasing the patient’s forced expiratory volume in 1 second (FEV1), increasing the patient’s forced vital capacity (FVC), increasing the patient’s peak expiratory flow rate (PEFR), or increasing the patient’s forced expiratory flow between 25% and 75% of FVC (FEF(25-75%)), as compared to the respective value for the patient prior treatment.

245. The method of claim 243 or 244, wherein the lung function is measured by spirometry.

246. A method for treating bronchiectasis in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.

247. The method of claim 246, wherein the bronchiectasis is non-cystic fibrosis bronchiectasis (NCFBE).

248. The method of claim 246, wherein the bronchiectasis is associated with cystic fibrosis.

249. The method of any one of claims 246-248, wherein treating comprises improving the lung function of the patient, as compared to the lung function of the patient prior to treatment.

250. The method of claim 249, wherein improving lung function of the patient comprises increasing the patient’s forced expiratory volume in 1 second (FEV1), increasing the patient’s forced vital capacity (FVC), increasing the patient’s peak expiratory flow rate (PEFR), or increasing the patient’s forced expiratory flow between 25% and 75% of FVC (FEF(25-75%)), as compared to the respective value for the patient prior to treatment.

251. The method of claim 249 or 250, wherein the lung function is measured by spirometry.

252. The method of any one of claims 246-251, wherein treating comprises decreasing the rate of pulmonary exacerbation, as compared to the rate of pulmonary exacerbation of the patient prior to treatment.Attorney Docket No.: INMD-209 / 01WO 315953-4493253. The method of any one of claims 246-252, wherein treating comprises increasing the time to first pulmonary exacerbation, as compared to an untreated patient.

254. The method of claim 252 or 253, wherein the pulmonary exacerbation is characterized by three or more of the following symptoms exhibited for at least 48 hours by the patient: (1) increased cough; (2) increased sputum volume or change in sputum consistency; (3) increased sputum purulence; (4) increased breathlessness and / or decreased exercise tolerance; (5) fatigue and / or malaise; (6) hemoptysis.

255. A method for treating chronic rhinosinusitis (CRS) in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.

256. The method of claim 255, wherein the chronic rhinosinusitis is chronic rhinosinusitis without nasal polyps (CRSsNP).

257. The method of claim 255, wherein the chronic rhinosinusitis is chronic rhinosinusitis with nasal polyps (CRSwNP).

258. The method of any one of claims 255-257, wherein the chronic rhinosinusitis is refractory chronic rhinosinusitis.

259. The method of any one of claims 255-258, wherein treating comprises reducing, diminishing the severity of, delaying the onset of, or eliminating one or more symptoms of CRS.

260. The method of claim 259, wherein the one or more symptoms of CRS is nasal congestion; nasal obstruction; nasal discharge; post-nasal drip; facial pressure; facial pain; facial fullness; reduced smell; depression; mucosal edema; mucopurulent discharge; obstruction of the middle meatus; mucosal changes within the ostiomeatal complex and sinuses; or rhinorrhea.

261. A method for treating hidradenitis suppurativa (HS) in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.

262. The method of claim 261, wherein the hidradenitis suppurativa (HS) is Hurley stage I.

263. The method of claim 261, wherein the hidradenitis suppurativa (HS) is Hurley stage II.Attorney Docket No.: INMD-209 / 01WO 315953-4493264. The method of claim 261, wherein the hidradenitis suppurativa (HS) is Hurley stage III.

265. A method for treating cancer in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.

266. The method of claim 265, wherein the cancer is a metastatic cancer.

267. The method of claim 266, wherein the metastatic cancer is breast to lung metastatic cancer.

268. The method of claim 266, wherein the metastatic cancer comprises metastasis of breast cancer to the brain, bone, pancreas, lymph nodes or liver.

269. The method of claim 266, wherein the metastatic cancer comprises metastasis of bone cancer to the lung.

270. The method of claim 266, wherein the metastatic cancer comprises metastasis of colorectal cancer to the peritoneum, the pancreas, the stomach, the lung, the liver, the kidney, or the spleen.

271. The method of claim 266, wherein the metastatic cancer comprises metastasis of stomach cancer to the mesentery, the spleen, the pancreas, the lung, the liver, the adrenal gland, or the ovary.

272. The method of claim 266, wherein the metastatic cancer comprises metastasis of liver cancer to the intestine, spleen, pancreas, stomach, lung, or the kidney.

273. The method of claim 266, wherein the metastatic cancer comprises metastasis of lymphoma to the kidney, ovary, liver, bladder, or the spleen.

274. A method for treating lupus nephritis in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-208or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 209.

275. A method for treating rheumatoid arthritis in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.Attorney Docket No.: INMD-209 / 01WO 315953-4493276. A method for treating inflammatory bowel disease (IBD) in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.

277. The method of claim 276, wherein the inflammatory bowel disease (IBD) is Crohn’s disease.

278. The method of claim 276, wherein the inflammatory bowel disease (IBD) is ulcerative colitis.

279. A method for treating an anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.

280. The method of claim 279, wherein the ANCA associated disease is granulomatosis with polyangiitis (GPA).

281. The method of claim 279, wherein the ANCA associated disease is microscopic polyangiitis (MPA).

282. A method for treating a disease in a patient in need thereof comprising, administering to the patient, an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211, wherein the disease is giant cell arteritis, polyarteritis nodosa, anti-GBM disease (Goodpasture’s), systemic scleroderma, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic ulcers, Duchenne muscular dystrophy, bronchiolitis obliterans, atopic dermatitis, pyoderma gangrenosum, sweet’s syndrome, dermatomyositis / polymyositis, neutrophilic dermatoses, thrombosis, bronchopulmonary dysplasia, amyotrophic lateral sclerosis, sickle cell anemia, psoriasis, or a ventilator-induced lung injury.

283. A method for treating a heart failure in a patient in need thereof, comprising administering to the patient, an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.Attorney Docket No.: INMD-209 / 01WO 315953-4493284. The method of claim 283, wherein the heart failure is heart failure with reduced ejection fraction.

285. The method of claim 283, wherein the heart failure is heart failure with preserved ejection fraction.

286. A method for treating ischemia / reperfusion (IR) injury in a patient in need thereof comprising, administering to the patient, an effective amount of a compound of any one of claims 1-210, or the composition of claim 211.

287. The method of claim 286, wherein the patient is a heart transplant recipient.

288. The method of claim 286 or 287, wherein the IR injury is due to heart transplantation.

289. The method of any one of claims 286-288, wherein the treating comprises improving left-ventricular (LV) graft function of the patient.

290. The method of claim 289, wherein improving left-ventricular (LV) graft function comprises improving LV systolic function of the patient.

291. The method of claim 290, wherein improving left-ventricular (LV) systolic function of the patient comprises improving LV systolic pressure (LVSP), developed pressure, maximal slope of systolic pressure increment (dP / dtmax), the rate pressure product (mmHg*bpm) of the patient, or a combination thereof.

292. A method for treating osteoarthritis (OA) in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.

293. A method for treating liver injury in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.

294. The method of claim 293, wherein the liver injury is drug-induced acute liver injury.

295. A method for treating neutrophilic asthma injury in a patient in need thereof, comprising, administering to the patient, an effective amount of a compound of any one of claims 1-210 or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, or the composition of claim 211.Attorney Docket No.: INMD-209 / 01WO 315953-4493296. The method of any one of claims 212-295, wherein the effective amount of the compound or composition is administered once daily during an administration period.

297. The method of any one of claims 212-296, wherein the effective amount of the compound or composition is administered orally.

Images